[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"_public_publisher_byId_7afcd79d-bb53-4ee4-9455-4e1539e045a2":3,"_public_publication_all{\"sortAscending\":false,\"sortField\":\"updateTime\",\"page\":0,\"size\":10,\"facet\":true,\"searchKey\":\"publisherId:7afcd79d-bb53-4ee4-9455-4e1539e045a2,\"}":65},{"code":4,"data":5,"meta":22},"SUCCESS",{"id":6,"createTime":7,"updateTime":8,"relativeEntities":9,"slug":10,"properties":11,"entityType":20,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":23,"subjectFields":24,"manageAffiliations":37,"indexDatabases":45,"url":64,"thumbnailPath":22,"statistic":22,"gsStatistic":22,"type":22,"analyzePriority":22},"7afcd79d-bb53-4ee4-9455-4e1539e045a2","2023-05-29T10:28:51.527+00:00","2025-11-21T09:51:41.057+00:00",[],"Surgical-Neurology-International",{"country":12,"issn":14,"title":16,"introduce":18},{"VOID":13},"IN",{"VOID":15},"21527806",{"EN":17},"Surgical Neurology International",{"EN":19},"Surgical Neurology International® (SNI) is an open access, Internet-only journal that publishes the latest developments in the field of neurosurgery and related clinical and basic neurosciences. SNI® will also discuss timely and controversial clinical, social, ethical, and political subjects related to the neurosciences of its readers worldwide. SNI® is an independent publication that is not affiliated with any society or organization. The journal welcomes papers and opinions from neurosurgeons and clinical and basic neuroscientists everywhere. Articles submitted to SNI must undergo a double-blind peer review process. SNI publishes on a continuous basis, currently averaging 25 articles per month. Its papers can be downloaded for free by anyone.","PUBLISHER","PENDING",null,0,[25,31],{"id":26,"createTime":22,"updateTime":22,"relativeEntities":27,"label":28,"description":30,"parentId":22,"standard":22,"scholarHubFieldId":22},"f3c7480d-9f85-464a-ad0d-807993a45c26",[],{"EN":29},"Surgery",{},{"id":32,"createTime":22,"updateTime":22,"relativeEntities":33,"label":34,"description":36,"parentId":22,"standard":22,"scholarHubFieldId":22},"228d6ea6-4b2a-4153-bf22-36784b0cd31c",[],{"EN":35},"Neurology (clinical)",{},[38],{"id":39,"createTime":22,"updateTime":22,"relativeEntities":40,"slug":22,"properties":41,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":44,"statistic":22},"dc0662fa-29b5-474d-a7dc-bf20dce6a5bc",[],{"title":42},{"EN":43},"Scientific Scholar LLC",[],[46],{"id":47,"indexDatabase":48,"url":58,"indexYears":59,"academicFieldIds":60,"indexDatabaseRanking":63},"87a05238-1043-4f16-ab38-3123c560330c",{"id":49,"createTime":22,"updateTime":22,"relativeEntities":50,"label":51,"description":53,"key":55,"publicationTags":56,"standard":22},"3c7051d4-eb7d-4c57-a56b-36fc74c5d1e9",[],{"EN":52,"VI":52},"Scopus - Elsevier",{"EN":52,"VI":54},"Cơ sở dữ liệu Scopus thuộc Elsevier","scopus",[57],"SCOPUS","https:\u002F\u002Fwww.scopus.com\u002Fsourceid\u002F19700201171","2011-2025",[61,62],"d729cb0b-d468-4829-9bfc-9e3b992eeefe","c75f06a2-b70a-4b9b-8c02-99f3ab012851","SCOPUS__Q3","https:\u002F\u002Fsurgicalneurologyint.com\u002F",{"meta":66,"data":68},{"total":67},"20",[69,1058,1218,1533,1745,1965,2140,2337,2546,2785],{"id":70,"createTime":71,"updateTime":71,"relativeEntities":72,"slug":73,"properties":74,"entityType":87,"verifyStatus":88,"verifyTime":71,"verifyNote":89,"languages":90,"translateLanguages":22,"viewCount":23,"primaryUrl":92,"fullTextUrl":22,"authors":93,"publicationType":147,"publisherRelationship":148,"citationCount":185,"citationInfo":186,"publishDate":199,"publishYear":187,"citationAnalyzeStatus":21,"lastCitationAnalyze":22,"indexDatabases":200,"openAccess":22,"references":201,"isForceReanalyzing":1057},"e3fad7aa-20c4-4aa5-85a0-848da8e73870","2025-02-11T07:13:05.805+00:00",[],"Glioblastoma-multiforme-State-of-the-art-and-future-therapeutics",{"openalex":75,"mag":77,"title":79,"pm":81,"doi":83,"pmc":85},{"VOID":76},"W2003438982",{"VOID":78},"2003438982",{"EN":80},"Glioblastoma multiforme: State of the art and future therapeutics",{"VOID":82},"24991467",{"VOID":84},"10.4103\u002F2152-7806.132138",{"VOID":86},"4078454","PUBLICATION","VERIFIED","Auto Verify",[91],"EN","http:\u002F\u002Fsurgicalneurologyint.com\u002Fsurgicalint-articles\u002Fglioblastoma-multiforme-state-of-the-art-and-future-therapeutics\u002F",[94,111,127],{"id":95,"sortIndex":23,"researcher":22,"roles":96,"affiliations":97,"properties":106,"displayName":108,"givenName":22,"familyName":22},"a46b65b0-9cc3-4a71-bf1e-01d3467b0e98",[],[98],{"id":99,"sortIndex":23,"affiliation":100,"properties":22},"590536a8-21f1-4563-ad41-91330819698a",{"id":99,"createTime":22,"updateTime":22,"relativeEntities":101,"slug":22,"properties":102,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":105,"statistic":22},[],{"title":103},{"EN":104},"Department of Neurosurgery, Division of Oncology, New York University School of Medicine, NY, USA.",[],{"title":107,"openalex":109},{"EN":108},"DavidH. Harter",{"VOID":110},"A5111625474",{"id":112,"sortIndex":113,"researcher":22,"roles":114,"affiliations":115,"properties":122,"displayName":124,"givenName":22,"familyName":22},"fdcb7a52-03cc-48a2-bc45-762759e8c1e6",1,[],[116],{"id":99,"sortIndex":23,"affiliation":117,"properties":22},{"id":99,"createTime":22,"updateTime":22,"relativeEntities":118,"slug":22,"properties":119,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":121,"statistic":22},[],{"title":120},{"EN":104},[],{"title":123,"openalex":125},{"EN":124},"TaylorA Wilson",{"VOID":126},"A5111625475",{"id":128,"sortIndex":129,"researcher":22,"roles":130,"affiliations":131,"properties":140,"displayName":144,"givenName":22,"familyName":22},"4c2d34a5-c16e-4a15-89fb-25c9e6916949",2,[],[132],{"id":133,"sortIndex":23,"affiliation":134,"properties":22},"02d5be43-888e-432d-ba96-a01500a8523d",{"id":133,"createTime":22,"updateTime":22,"relativeEntities":135,"slug":22,"properties":136,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":139,"statistic":22},[],{"title":137},{"EN":138},"Department of Pediatrics, Division of Oncology, New York University School of Medicine, NY, USA.",[],{"orcid":141,"title":143,"openalex":145},{"VOID":142},"https:\u002F\u002Forcid.org\u002F0000-0002-7151-6528",{"EN":144},"Matthias A. Karajannis",{"VOID":146},"A5007528270","ARTICLE",{"url":22,"publisher":149,"properties":178},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":150,"slug":10,"properties":151,"entityType":20,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":23,"subjectFields":155,"manageAffiliations":164,"indexDatabases":170,"url":64,"thumbnailPath":22,"statistic":22,"gsStatistic":22,"type":22,"analyzePriority":22},[],{"issn":152,"title":153,"country":154},{"VOID":15},{"EN":17},{"VOID":13},[156,160],{"id":26,"createTime":22,"updateTime":22,"relativeEntities":157,"label":158,"description":159,"parentId":22,"standard":22,"scholarHubFieldId":22},[],{"EN":29},{},{"id":32,"createTime":22,"updateTime":22,"relativeEntities":161,"label":162,"description":163,"parentId":22,"standard":22,"scholarHubFieldId":22},[],{"EN":35},{},[165],{"id":39,"createTime":22,"updateTime":22,"relativeEntities":166,"slug":22,"properties":167,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":169,"statistic":22},[],{"title":168},{"EN":43},[],[171],{"id":47,"indexDatabase":172,"url":58,"indexYears":59,"academicFieldIds":177,"indexDatabaseRanking":63},{"id":49,"createTime":22,"updateTime":22,"relativeEntities":173,"label":174,"description":175,"key":55,"publicationTags":176,"standard":22},[],{"EN":52,"VI":52},{"EN":52,"VI":54},[57],[61,62],{"issue":179,"pages":181,"volume":183},{"VOID":180},"1",{"VOID":182},"64",{"VOID":184},"5",289,{"total":185,"publishYear":187,"statisticByYear":188},2014,{"2014":189,"2015":190,"2016":191,"2017":192,"2018":193,"2019":194,"2020":195,"2021":190,"2022":196,"2023":197,"2024":198},7,30,29,18,22,31,23,43,32,24,"2014-01-01",[63],[202,205,208,211,214,217,220,223,226,229,232,235,238,241,244,247,250,253,256,259,262,265,268,271,274,277,280,283,286,289,292,295,298,301,304,307,310,313,316,319,322,325,328,331,334,337,340,343,346,349,352,355,358,361,364,367,370,373,376,379,382,385,388,391,394,397,400,403,406,409,412,415,418,421,424,427,430,433,436,439,442,445,449,452,455,458,461,464,467,470,473,476,479,482,485,488,491,494,497,500,503,506,509,512,515,518,521,524,527,530,533,536,539,542,545,548,551,554,557,560,563,566,569,572,575,578,581,584,587,590,593,596,599,602,605,608,611,614,617,620,623,626,629,632,635,638,641,644,647,650,653,656,659,662,665,668,671,674,677,680,683,686,689,692,695,698,701,704,707,710,713,716,719,722,725,728,731,734,737,740,743,746,749,752,755,758,761,764,767,770,773,776,779,782,785,788,791,794,797,800,803,806,809,812,815,818,821,824,827,830,833,836,839,842,845,848,851,854,857,860,863,866,869,872,875,878,881,884,887,890,893,896,899,903,906,909,912,915,918,921,924,927,930,933,936,939,942,945,948,951,954,957,960,963,966,969,973,976,979,982,985,988,991,994,997,1000,1003,1006,1009,1012,1015,1018,1021,1024,1027,1030,1033,1036,1039,1042,1045,1048,1051,1054],{"id":22,"text":203,"url":22,"identifiers":204},"Aguilar, 2012, Curr Treat Options Oncol, The spectrum of vaccine therapies for patients with glioblastoma multiforme, 437",{},{"id":22,"text":206,"url":22,"identifiers":207},"Ahmed, 2011, Mol Ther, Neural stem cell-based cell carriers enhance therapeutic efficacy of an oncolytic adenovirus in an orthotopic mouse model of human glioblastoma, 1714",{},{"id":22,"text":209,"url":22,"identifiers":210},"Ahmed, 2011, Mol Pharm, A comparative study of neural and mesenchymal stem cell-based carriers for oncolytic adenovirus in a model of malignant glioma, 1559",{},{"id":22,"text":212,"url":22,"identifiers":213},"Anton, 2012, Hematol Oncol Clin North Am, Glioblastoma multiforme: Overview of current treatment and future perspectives, 825",{},{"id":22,"text":215,"url":22,"identifiers":216},"Ardon, 2010, Pediatr Blood Cancer, Adjuvant dendritic cell-based tumour vaccination for children with malignant brain tumours, 519",{},{"id":22,"text":218,"url":22,"identifiers":219},"Ardon, 2010, J Neurooncol, Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: A pilot study, 261",{},{"id":22,"text":221,"url":22,"identifiers":222},"Arjona, 2006, Curr Mol Med, Early genetic changes involved in low-grade astrocytic tumor development, 645",{},{"id":22,"text":224,"url":22,"identifiers":225},"Bai, 2011, Trends Mol Med, Molecular targeting of glioblastoma: Drug discovery and therapies, 301",{},{"id":22,"text":227,"url":22,"identifiers":228},"Balss, 2008, Acta Neuropathol, Analysis of the IDH1 codon 132 mutation in brain tumors, 597",{},{"id":22,"text":230,"url":22,"identifiers":231},"Bao, 2006, Nature, Glioma stem cells promote radioresistance by preferential activation of the DNA damage response, 756",{},{"id":22,"text":233,"url":22,"identifiers":234},"Barba, 1989, J Neurosurg, Intratumoral LAK cell and interleukin-2 therapy of human gliomas, 175",{},{"id":22,"text":236,"url":22,"identifiers":237},"Batchelor, 2010, J Clin Oncol, Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma, 2817",{},{"id":22,"text":239,"url":22,"identifiers":240},"Bello, 2001, Neurosurgery, Alpha(v)beta3 and alpha(v)beta5 integrin expression in glioma periphery, 380",{},{"id":22,"text":242,"url":22,"identifiers":243},"Beltinger, 1999, Proc Natl Acad Sci U S A, Herpes simplex virus thymidine kinase\u002Fganciclovir-induced apoptosis involves ligand-independent death receptor aggregation and activation of caspases, 8699",{},{"id":22,"text":245,"url":22,"identifiers":246},"Beroukhim, 2007, Proc Natl Acad Sci U S A, Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma, 20007",{},{"id":22,"text":248,"url":22,"identifiers":249},"Bigner, 1995, J Neurooncol, Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab′) 2--a preliminary report, 109",{},{"id":22,"text":251,"url":22,"identifiers":252},"Blancher, 1993, Eur Cytokine Netw, Local immunotherapy of recurrent glioblastoma multiforme by intracerebral perfusion of interleukin-2 and LAK cells, 331",{},{"id":22,"text":254,"url":22,"identifiers":255},"Boiardi, 1994, Cancer Immunol Immunother, Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients, 193",{},{"id":22,"text":257,"url":22,"identifiers":258},"Brady, 1992, Int J Radiat Oncol Biol Phys, Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: A phase II trial, 225",{},{"id":22,"text":260,"url":22,"identifiers":261},"Brennan, 2009, PloS One, Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations, e7752",{},{"id":22,"text":263,"url":22,"identifiers":264},"Brown, 2008, J Clin Oncol, Phase I\u002FII trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177, 5603",{},{"id":22,"text":266,"url":22,"identifiers":267},"Buchschacher, 2000, Blood, Development of lentiviral vectors for gene therapy for human diseases, 2499",{},{"id":22,"text":269,"url":22,"identifiers":270},"Cahoy, 2008, J Neurosci, A transcriptome database for astrocytes, neurons, and oligodendrocytes: A new resource for understanding brain development and function, 264",{},{"id":22,"text":272,"url":22,"identifiers":273},"Calabrese, 2007, Cancer Cell, A perivascular niche for brain tumor stem cells, 69",{},{"id":22,"text":275,"url":22,"identifiers":276},"Cancer, 2008, Nature, Comprehensive genomic characterization defines human glioblastoma genes and core pathways, 1061",{},{"id":22,"text":278,"url":22,"identifiers":279},"Candolfi, 2009, Clin Cancer Res, Release of HMGB1 in response to proapoptotic glioma killing strategies: Efficacy and neurotoxicity, 4401",{},{"id":22,"text":281,"url":22,"identifiers":282},"Caruso, 2004, Neuro Oncol, Results of a phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer, 236",{},{"id":22,"text":284,"url":22,"identifiers":285},"Castro, 2011, Curr Gene Ther, Gene therapy and targeted toxins for glioma, 155",{},{"id":22,"text":287,"url":22,"identifiers":288},"Chambers, 1995, Proc Natl Acad Sci U S A, Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma, 1411",{},{"id":22,"text":290,"url":22,"identifiers":291},"Chang, 2011, J Clin Neurosci, A phase I\u002FII clinical trial investigating the adverse and therapeutic effects of a postoperative autologous dendritic cell tumor vaccine in patients with malignant glioma, 1048",{},{"id":22,"text":293,"url":22,"identifiers":294},"Chaudhry, 2001, Histopathology, Vascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomas, 409",{},{"id":22,"text":296,"url":22,"identifiers":297},"Chen, 2012, Nature, A restricted cell population propagates glioblastoma growth after chemotherapy, 522",{},{"id":22,"text":299,"url":22,"identifiers":300},"Chen, 2012, Cell, Malignant glioma: Lessons from genomics, mouse models, and stem cells, 36",{},{"id":22,"text":302,"url":22,"identifiers":303},"Chinot, 2007, J Clin Oncol, Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide, 1470",{},{"id":22,"text":305,"url":22,"identifiers":306},"Chinot, 2011, Adv Ther, AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme, 334",{},{"id":22,"text":308,"url":22,"identifiers":309},"Chiocca, 2004, Mol Ther, A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting, 958",{},{"id":22,"text":311,"url":22,"identifiers":312},"Choi, 2009, Brain Pathol, EGFRvIII-targeted vaccination therapy of malignant glioma, 713",{},{"id":22,"text":314,"url":22,"identifiers":315},"Chow, 2011, Immunotherapy, Cellular immunotherapy for high-grade glioma, 423",{},{"id":22,"text":317,"url":22,"identifiers":318},"Clarke, 2010, Arch Neurol, Recent advances in therapy for glioblastoma, 279",{},{"id":22,"text":320,"url":22,"identifiers":321},"Cloughesy, 2006, J Clin Oncol, Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: A North American Brain Tumor Consortium Study, 3651",{},{"id":22,"text":323,"url":22,"identifiers":324},"Cloughesy, 2008, PLoS Med, Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma, e8",{},{"id":22,"text":326,"url":22,"identifiers":327},"Combs, 2006, BMC Cancer, Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT)--phase I\u002FII trial: Study protocol, 133",{},{"id":22,"text":329,"url":22,"identifiers":330},"Corey, 1986, Diagn Microbiol Infect Dis, Laboratory diagnosis of herpes simplex virus infections.Principles guiding the development of rapid diagnostic tests, 111",{},{"id":22,"text":332,"url":22,"identifiers":333},"Curtin, 2009, PLoS Med, HMGB1 mediates endogenous TLR2 activation and brain tumor regression, e10",{},{"id":22,"text":335,"url":22,"identifiers":336},"Cutter, 2006, Expert Rev Anticancer Ther, Gene therapeutics: The future of brain tumor therapy?, 1053",{},{"id":22,"text":338,"url":22,"identifiers":339},"Day ED, Lassiter S, Woodhall B, Mahaley JL, Mahaley MS Jr. The localization of radioantibodies in human brain tumors. I. Preliminary exploration. Cancer Res 1965;25:773-8.",{},{"id":22,"text":341,"url":22,"identifiers":342},"Day, 2012, Neurosurg Clin N Am, Clinical trials of small molecule inhibitors in high-grade glioma, 407",{},{"id":22,"text":344,"url":22,"identifiers":345},"De, 2008, Clin Cancer Res, Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme, 3098",{},{"id":22,"text":347,"url":22,"identifiers":348},"Debinski, 2000, Mol Med, Molecular expression analysis of restrictive receptor for interleukin 13, a brain tumor-associated cancer\u002Ftestis antigen, 440",{},{"id":22,"text":350,"url":22,"identifiers":351},"Debinski, 1999, Int J Oncol, Receptor for interleukin 13 is abundantly and specifically over-expressed in patients with glioblastoma multiforme, 481",{},{"id":22,"text":353,"url":22,"identifiers":354},"Debinski, 1996, J Biol Chem, Receptor for interleukin (IL) 13 does not interact with IL4 but receptor for IL4 interacts with IL13 on human glioma cells, 22428",{},{"id":22,"text":356,"url":22,"identifiers":357},"Debinski, 1995, Clin Cancer Res, Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin, 1253",{},{"id":22,"text":359,"url":22,"identifiers":360},"Debinski, 2000, J Neurooncol, Expression of a restrictive receptor for interleukin 13 is associated with glial transformation, 103",{},{"id":22,"text":362,"url":22,"identifiers":363},"Del, 2010, Curr Opin Mol Ther, Rindopepimut, a 14-mer injectable peptide vaccine against EGFRvIII for the potential treatment of glioblastoma multiforme, 741",{},{"id":22,"text":365,"url":22,"identifiers":366},"Dembinski, 2010, Cancer Gene Ther, Reduction of nontarget infection and systemic toxicity by targeted delivery of conditionally replicating viruses transported in mesenchymal stem cells, 289",{},{"id":22,"text":368,"url":22,"identifiers":369},"Dillman, 2011, Cancer Biother Radiopharm, Cancer immunotherapy, 1",{},{"id":22,"text":371,"url":22,"identifiers":372},"Dillman, 2009, J Immunother, Intralesional lymphokine-activated killer cells as adjuvant therapy for primary glioblastoma, 914",{},{"id":22,"text":374,"url":22,"identifiers":375},"Dillman, 2004, J Immunother, Intracavitary placement of autologous lymphokine-activated killer (LAK) cells after resection of recurrent glioblastoma, 398",{},{"id":22,"text":377,"url":22,"identifiers":378},"Dirks, 2008, J Clin Oncol, Brain tumor stem cells: Bringing order to the chaos of brain cancer, 2916",{},{"id":22,"text":380,"url":22,"identifiers":381},"Drablos, 2004, DNA Repair (Amst), Alkylation damage in DNA and RNA--repair mechanisms and medical significance, 1389",{},{"id":22,"text":383,"url":22,"identifiers":384},"Dresemann, 2005, Ann Oncol, Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: A patient series, 1702",{},{"id":22,"text":386,"url":22,"identifiers":387},"Dvorak, 2002, J Clin Oncol, Vascular permeability factor\u002Fvascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy, 4368",{},{"id":22,"text":389,"url":22,"identifiers":390},"Ehtesham, 2004, Cancer Control, Recent progress in immunotherapy for malignant glioma: Treatment strategies and results from clinical trials, 192",{},{"id":22,"text":392,"url":22,"identifiers":393},"El-Aneed, 2004, J Control Release, An overview of current delivery systems in cancer gene therapy, 1",{},{"id":22,"text":395,"url":22,"identifiers":396},"Eller, 2005, Neurosurgery, Anti-epidermal growth factor receptor monoclonal antibody cetuximab augments radiation effects in glioblastoma multiforme in vitro and in vivo, 155",{},{"id":22,"text":398,"url":22,"identifiers":399},"Ferguson, 2010, Discov Med, Crossing the boundaries: Stem cells and gene therapy, 192",{},{"id":22,"text":401,"url":22,"identifiers":402},"Ferrara, 2005, Oncology, VEGF as a therapeutic target in cancer, 11",{},{"id":22,"text":404,"url":22,"identifiers":405},"Ferrara, 2009, Eur Cytokine Netw, VEGF-A: A critical regulator of blood vessel growth, 158",{},{"id":22,"text":407,"url":22,"identifiers":408},"Ferrara, 2003, Nat Med, The biology of VEGF and its receptors, 669",{},{"id":22,"text":410,"url":22,"identifiers":411},"Floeth, 2001, Cancer Gene Ther, Local inflammation and devascularization--in vivo mechanisms of the \"bystander effect\" in VPC-mediated HSV-Tk\u002FGCV gene therapy for human malignant glioma, 843",{},{"id":22,"text":413,"url":22,"identifiers":414},"Forsyth, 2008, Mol Ther, A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas, 627",{},{"id":22,"text":416,"url":22,"identifiers":417},"Friedman, 2009, J Clin Oncol, Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma, 4733",{},{"id":22,"text":419,"url":22,"identifiers":420},"Fueyo, 2003, J Natl Cancer Inst, Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway, 652",{},{"id":22,"text":422,"url":22,"identifiers":423},"Fueyo, 2000, Oncogene, A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo, 2",{},{"id":22,"text":425,"url":22,"identifiers":426},"Fujisawa, 2000, Lab Invest, Loss of heterozygosity on chromosome 10 is more extensive in primary (de novo) than in secondary glioblastomas, 65",{},{"id":22,"text":428,"url":22,"identifiers":429},"Fukai, 2008, Cancer Sci, Antitumor activity of cetuximab against malignant glioma cells overexpressing EGFR deletion mutant variant III, 2062",{},{"id":22,"text":431,"url":22,"identifiers":432},"Furnari, 2007, Genes Dev, Malignant astrocytic glioma: Genetics, biology, and paths to treatment, 2683",{},{"id":22,"text":434,"url":22,"identifiers":435},"Galanis, 2005, J Clin Oncol, Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A North Central Cancer Treatment Group Study, 5294",{},{"id":22,"text":437,"url":22,"identifiers":438},"Geoerger, 2002, Cancer Res, Oncolytic activity of the E1B-55 kDa-deleted adenovirus ONYX-015 is independent of cellular p53 status in human malignant glioma xenografts, 764",{},{"id":22,"text":440,"url":22,"identifiers":441},"Germano, 2003, J Neurooncol, Adenovirus\u002Fherpes simplex-thymidine kinase\u002Fganciclovir complex: Preliminary results of a phase I trial in patients with recurrent malignant gliomas, 279",{},{"id":22,"text":443,"url":22,"identifiers":444},"Gerson, 2004, Nat Rev Cancer, MGMT: Its role in cancer aetiology and cancer therapeutics, 296",{},{"id":22,"text":446,"url":22,"identifiers":447},"Gilbert M, editor RTOG 0825: Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM). 2013 ASCO Annual Meeting; 2013; Chicago.",{"doi":448},"10.1200\u002Fjco.2013.31.18_suppl.1",{"id":22,"text":450,"url":22,"identifiers":451},"Gomez-Manzano, 2012, Handb Clin Neurol, Gene therapy, 331",{},{"id":22,"text":453,"url":22,"identifiers":454},"Grandi, 2009, Expert Rev Neurother, Design and application of oncolytic HSV vectors for glioblastoma therapy, 505",{},{"id":22,"text":456,"url":22,"identifiers":457},"Haas-Kogan, 2005, J Natl Cancer Inst, Epidermal growth factor receptor, protein kinase B\u002FAkt, and glioma response to erlotinib, 880",{},{"id":22,"text":459,"url":22,"identifiers":460},"Han, 2007, J Gene Med, Development of a second-generation oncolytic Herpes simplex virus expressing TNFalpha for cancer therapy, 99",{},{"id":22,"text":462,"url":22,"identifiers":463},"Harsh, 2000, J Neurosurg, Thymidine kinase activation of ganciclovir in recurrent malignant gliomas: A gene-marking and neuropathological study, 804",{},{"id":22,"text":465,"url":22,"identifiers":466},"Hart, 2008, Cochrane Database Syst Rev, Chemotherapeutic wafers for High Grade Glioma, CD007294",{},{"id":22,"text":468,"url":22,"identifiers":469},"Hasselbalch, 2010, Neuro Oncol, Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: A phase II trial, 508",{},{"id":22,"text":471,"url":22,"identifiers":472},"Hasselbalch, 2010, Cancer Invest, Cetuximab insufficiently inhibits glioma cell growth due to persistent EGFR downstream signaling, 775",{},{"id":22,"text":474,"url":22,"identifiers":475},"Hawasli, 2013, Neurosurgery, Magnetic resonance imaging-guided focused laser interstitial thermal therapy for intracranial lesions: Single-institution series, 1007",{},{"id":22,"text":477,"url":22,"identifiers":478},"Hayes, 2001, Crit Rev Oncol Hematol, Adoptive cellular immunotherapy for the treatment of malignant gliomas, 31",{},{"id":22,"text":480,"url":22,"identifiers":481},"Hayes, 1995, Cancer, Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma, 840",{},{"id":22,"text":483,"url":22,"identifiers":484},"Hegi, 2005, N Engl J Med, MGMT gene silencing and benefit from temozolomide in glioblastoma, 997",{},{"id":22,"text":486,"url":22,"identifiers":487},"Heimberger, 2009, Expert Opin Biol Ther, The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients, 1087",{},{"id":22,"text":489,"url":22,"identifiers":490},"Holladay, 1996, J Neurooncol, Autologous tumor cell vaccination combined with adoptive cellular immunotherapy in patients with grade III\u002FIV astrocytoma, 179",{},{"id":22,"text":492,"url":22,"identifiers":493},"Hoover, 2010, Neuroimaging Clin N Am, Clinical trials in brain tumor surgery, 409",{},{"id":22,"text":495,"url":22,"identifiers":496},"Immonen, 2004, Mol Ther, AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: A randomised, controlled study, 967",{},{"id":22,"text":498,"url":22,"identifiers":499},"Iwami, 2010, Neurol Med Chir, Gene therapy for high-grade glioma, 727",{},{"id":22,"text":501,"url":22,"identifiers":502},"Izquierdo, 1997, Acta Neurochir Suppl, Gene therapy in brain tumours: Implications of the size of glioblastoma on its curability, 111",{},{"id":22,"text":504,"url":22,"identifiers":505},"Izquierdo, 1996, Gene Ther, Human malignant brain tumor response to herpes simplex thymidine kinase (HSVtk)\u002Fganciclovir gene therapy, 491",{},{"id":22,"text":507,"url":22,"identifiers":508},"Jacobs, 1999, Neoplasia, HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: Part I.HSV-1 structure, replication and pathogenesis, 387",{},{"id":22,"text":510,"url":22,"identifiers":511},"Jacobs, 1999, Neoplasia, HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: Part II.Vector systems and applications, 402",{},{"id":22,"text":513,"url":22,"identifiers":514},"Jacobs, 1986, Cancer Res, Interleukin-2 or autologous lymphokine-activated killer cell treatment of malignant glioma: Phase I trial, 2101",{},{"id":22,"text":516,"url":22,"identifiers":517},"Jain, 2007, Nat Rev Neurosci, Angiogenesis in brain tumours, 610",{},{"id":22,"text":519,"url":22,"identifiers":520},"Joshi, 2001, Cancer Res, In situ expression of interleukin-4 (IL-4) receptors in human brain tumors and cytotoxicity of a recombinant IL-4 cytotoxin in primary glioblastoma cell cultures, 8058",{},{"id":22,"text":522,"url":22,"identifiers":523},"Kahn, 1998, J Mag Reson Imaging, In vivo MRI thermometry using a phase-sensitive sequence: Preliminary experience during MRI-guided laser-induced interstitial thermotherapy of brain tumors, 160",{},{"id":22,"text":525,"url":22,"identifiers":526},"Kaina, 2007, DNA Repair (Amst), MGMT: Key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents, 1079",{},{"id":22,"text":528,"url":22,"identifiers":529},"Kalofonos, 1989, J Nucl Med, Antibody guided diagnosis and therapy of brain gliomas using radiolabeled monoclonal antibodies against epidermal growth factor receptor and placental alkaline phosphatase, 1636",{},{"id":22,"text":531,"url":22,"identifiers":532},"Kamoun, 2009, J Clin Oncol, Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice, 2542",{},{"id":22,"text":534,"url":22,"identifiers":535},"Kanaly, 2010, Neurosurg Clin N Am, Clinical applications of a peptide-based vaccine for glioblastoma, 95",{},{"id":22,"text":537,"url":22,"identifiers":538},"Kang, 2008, J Neurooncol, Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety, 113",{},{"id":22,"text":540,"url":22,"identifiers":541},"Kangasniemi, 2004, Lasers Surg Med, Thermal therapy of canine cerebral tumors using a 980 nm diode laser with MR temperature-sensitive imaging feedback, 41",{},{"id":22,"text":543,"url":22,"identifiers":544},"Kendall, 2008, Stem Cells, Neural stem cell targeting of glioma is dependent on phosphoinositide 3-kinase signaling, 1575",{},{"id":22,"text":546,"url":22,"identifiers":547},"Kikuchi, 2004, J Immunother, Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12, 452",{},{"id":22,"text":549,"url":22,"identifiers":550},"Kirson, 2007, Proc Natl Acad Sci U S A, Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors, 10152",{},{"id":22,"text":552,"url":22,"identifiers":553},"Kitahara, 1987, J Neurooncol, Establishment of interleukin 2 dependent cytotoxic T lymphocyte cell line specific for autologous brain tumor and its intracranial administration for therapy of the tumor, 329",{},{"id":22,"text":555,"url":22,"identifiers":556},"Kleihues, 1999, Neuro Oncol, Primary and secondary glioblastomas: From concept to clinical diagnosis, 44",{},{"id":22,"text":558,"url":22,"identifiers":559},"Kootstra, 2003, Annu Rev Pharmacol Toxicol, Gene therapy with viral vectors, 413",{},{"id":22,"text":561,"url":22,"identifiers":562},"Kranzler, 2009, Curr Gene Ther, Stem cells as delivery vehicles for oncolytic adenoviral virotherapy, 389",{},{"id":22,"text":564,"url":22,"identifiers":565},"Kreisl, 2009, J Clin Oncol, Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma, 740",{},{"id":22,"text":567,"url":22,"identifiers":568},"Kroeger, 2010, Discov Med, Gene therapy and virotherapy: Novel therapeutic approaches for brain tumors, 293",{},{"id":22,"text":570,"url":22,"identifiers":571},"Kruse, 1997, Cancer Immunol Immunother, Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2, 77",{},{"id":22,"text":573,"url":22,"identifiers":574},"Kunwar, 2010, Neuro Oncol, Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma, 871",{},{"id":22,"text":576,"url":22,"identifiers":577},"Kunwar, 2007, J Clin Oncol, Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: A report by the Cintredekin Besudotox Intraparenchymal Study Group, 837",{},{"id":22,"text":579,"url":22,"identifiers":580},"Latchman, 2001, Gene, Gene delivery and gene therapy with herpes simplex virus-based vectors, 1",{},{"id":22,"text":582,"url":22,"identifiers":583},"Lee, 2006, Cancer Cell, Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines, 391",{},{"id":22,"text":585,"url":22,"identifiers":586},"Leibel, 1987, J Neurosurg, Radiation therapy for neoplasms of the brain, 1",{},{"id":22,"text":588,"url":22,"identifiers":589},"Lewis, 1994, J Virol, Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus, 510",{},{"id":22,"text":591,"url":22,"identifiers":592},"Li, 2010, J Neurosurg, A Phase II study of anti-epidermal growth factor receptor radioimmunotherapy in the treatment of glioblastoma multiforme, 192",{},{"id":22,"text":594,"url":22,"identifiers":595},"Li, 2010, Toxins, Targeted toxins in brain tumor therapy, 2645",{},{"id":22,"text":597,"url":22,"identifiers":598},"Liau, 2005, Clin Cancer Res, Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment, 5515",{},{"id":22,"text":600,"url":22,"identifiers":601},"Lillehei, 1991, Neurosurgery, Long-term follow-up of patients with recurrent malignant gliomas treated with adjuvant adoptive immunotherapy, 16",{},{"id":22,"text":603,"url":22,"identifiers":604},"Long, 1998, Hum Gene Ther, Biosafety monitoring of patients receiving intracerebral injections of murine retroviral vector producer cells, 1165",{},{"id":22,"text":606,"url":22,"identifiers":607},"Long, 1999, Hum Gene Ther, Molecular evaluation of biopsy and autopsy specimens from patients receiving in vivo retroviral gene therapy, 733",{},{"id":22,"text":609,"url":22,"identifiers":610},"Luptrawan, 2008, Rev Recent Clin Trials, Dendritic cell immunotherapy for malignant gliomas, 10",{},{"id":22,"text":612,"url":22,"identifiers":613},"Mahaley MS Jr, Mahaley JL, Day ED. The localization of radioantibodies in human brain tumors. II. Radioautography. Cancer Res 1965;25:779-93.",{},{"id":22,"text":615,"url":22,"identifiers":616},"Markert, 2009, Mol Ther, Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM, 199",{},{"id":22,"text":618,"url":22,"identifiers":619},"Markert, 2000, Gene Ther, Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: Results of a phase I trial, 867",{},{"id":22,"text":621,"url":22,"identifiers":622},"Martinez, 2009, Epigenetics, A microarray-based DNA methylation study of glioblastoma multiforme, 255",{},{"id":22,"text":624,"url":22,"identifiers":625},"McGirt, 2009, J Neurosurg, Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme, 583",{},{"id":22,"text":627,"url":22,"identifiers":628},"Mellinghoff, 2007, Clin Cancer Res, PTEN-mediated resistance to epidermal growth factor receptor kinase inhibitors, 378",{},{"id":22,"text":630,"url":22,"identifiers":631},"Merchant, 1988, Cancer, Adoptive immunotherapy for recurrent glioblastoma multiforme using lymphokine activated killer cells and recombinant interleukin-2, 665",{},{"id":22,"text":633,"url":22,"identifiers":634},"Mesnil, 2000, Cancer Res, Bystander effect in herpes simplex virus-thymidine kinase\u002Fganciclovir cancer gene therapy: Role of gap-junctional intercellular communication, 3989",{},{"id":22,"text":636,"url":22,"identifiers":637},"Mintz, 2003, J Neurooncol, Molecular targeting with recombinant cytotoxins of interleukin-13 receptor alpha2-expressing glioma, 117",{},{"id":22,"text":639,"url":22,"identifiers":640},"Mintz, 2002, Neoplasia, IL-13Ralpha2 is a glioma-restricted receptor for interleukin-13, 388",{},{"id":22,"text":642,"url":22,"identifiers":643},"Mischel, 2003, Oncogene, Identification of molecular subtypes of glioblastoma by gene expression profiling, 2361",{},{"id":22,"text":645,"url":22,"identifiers":646},"Mitchell, 2008, Immunol Rev, Immunotherapy of malignant brain tumors, 70",{},{"id":22,"text":648,"url":22,"identifiers":649},"Mitchell, 2009, Neurotherapeutics, Toward effective immunotherapy for the treatment of malignant brain tumors, 527",{},{"id":22,"text":651,"url":22,"identifiers":652},"Mohanam, 1994, J Neurooncol, Proteolysis and invasiveness of brain tumors: Role of urokinase-type plasminogen activator receptor, 153",{},{"id":22,"text":654,"url":22,"identifiers":655},"Mohyeldin, 2012, Cancer J, Gene and viral therapy for glioblastoma: A review of clinical trials and future directions, 82",{},{"id":22,"text":657,"url":22,"identifiers":658},"Msaouel, 2009, Curr Opin Mol Ther, Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: An overview, 43",{},{"id":22,"text":660,"url":22,"identifiers":661},"Mueller, 2011, J Neurooncol, Effect of imaging and catheter characteristics on clinical outcome for patients in the PRECISE study, 267",{},{"id":22,"text":663,"url":22,"identifiers":664},"Murat, 2008, J Clin Oncol, Stem cell-related \"self-renewal\" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma, 3015",{},{"id":22,"text":666,"url":22,"identifiers":667},"Nakamura, 2000, J Neuropathol Exp Neurol, Loss of heterozygosity on chromosome 19 in secondary glioblastomas, 539",{},{"id":22,"text":669,"url":22,"identifiers":670},"Neyns, 2011, J Neurooncol, Phase II study of sunitinib malate in patients with recurrent high-grade glioma, 491",{},{"id":22,"text":672,"url":22,"identifiers":673},"Neyns, 2009, Ann Oncol, Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma, 1596",{},{"id":22,"text":675,"url":22,"identifiers":676},"Nobusawa, 2009, Clin Cancer Res, IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas, 6002",{},{"id":22,"text":678,"url":22,"identifiers":679},"Ohgaki, 2004, Cancer Res, Genetic pathways to glioblastoma: A population-based study, 6892",{},{"id":22,"text":681,"url":22,"identifiers":682},"Ohgaki, 2013, Clin Cancer Res, The definition of primary and secondary glioblastoma, 764",{},{"id":22,"text":684,"url":22,"identifiers":685},"Ohgaki, 2007, Am J Pathol, Genetic pathways to primary and secondary glioblastoma, 1445",{},{"id":22,"text":687,"url":22,"identifiers":688},"Ostman, 2004, Cytokine Growth Factor Rev, PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma, 275",{},{"id":22,"text":690,"url":22,"identifiers":691},"Parker, 2000, Proc Natl Acad Sci U S A, Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors, 2208",{},{"id":22,"text":693,"url":22,"identifiers":694},"Parsons, 2008, Science, An integrated genomic analysis of human glioblastoma multiforme, 1807",{},{"id":22,"text":696,"url":22,"identifiers":697},"Patel, 2012, Expert Opin Investig Drugs, Molecular targeted therapy in recurrent glioblastoma: Current challenges and future directions, 1247",{},{"id":22,"text":699,"url":22,"identifiers":700},"Peereboom, 2010, J Neurooncol, Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme, 93",{},{"id":22,"text":702,"url":22,"identifiers":703},"Pelloski, 2006, Clin Cancer Res, Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma, 3935",{},{"id":22,"text":705,"url":22,"identifiers":706},"Perry, 2012, Neurol Res Int, Novel therapies in glioblastoma, 428565",{},{"id":22,"text":708,"url":22,"identifiers":709},"Phillips, 2006, Cancer Cell, Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis, 157",{},{"id":22,"text":711,"url":22,"identifiers":712},"Piccirillo, 2006, Nature, Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells, 761",{},{"id":22,"text":714,"url":22,"identifiers":715},"Pichlmeier, 2008, Neuro Oncol, Resection and survival in glioblastoma multiforme: An RTOG recursive partitioning analysis of ALA study patients, 1025",{},{"id":22,"text":717,"url":22,"identifiers":718},"Pitter, 2011, PloS One, Perifosine and CCI 779 co-operate to induce cell death and decrease proliferation in PTEN-intact and PTEN-deficient PDGF-driven murine glioblastoma, e14545",{},{"id":22,"text":720,"url":22,"identifiers":721},"Plautz, 1998, J Neurosurg, Systemic T cell adoptive immunotherapy of malignant gliomas, 42",{},{"id":22,"text":723,"url":22,"identifiers":724},"Plautz, 2000, Clin Cancer Res, T cell adoptive immunotherapy of newly diagnosed gliomas, 2209",{},{"id":22,"text":726,"url":22,"identifiers":727},"Pollard, 2009, Cell Stem Cell, Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens, 568",{},{"id":22,"text":729,"url":22,"identifiers":730},"Prados, 2009, J Clin Oncol, Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma, 579",{},{"id":22,"text":732,"url":22,"identifiers":733},"Prados, 2006, Neuro Oncol, Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma, 67",{},{"id":22,"text":735,"url":22,"identifiers":736},"Prados, 2003, J Neurooncol, Treatment of progressive or recurrent glioblastoma multiforme in adults with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration: A phase I\u002FII multi-institutional trial, 269",{},{"id":22,"text":738,"url":22,"identifiers":739},"Prasad, 2011, Neuro Oncol, Inhibition of PI3K\u002FmTOR pathways in glioblastoma and implications for combination therapy with temozolomide, 384",{},{"id":22,"text":741,"url":22,"identifiers":742},"Presta, 1997, Cancer Res, Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders, 4593",{},{"id":22,"text":744,"url":22,"identifiers":745},"Prins, 2011, Clin Cancer Res, Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy, 1603",{},{"id":22,"text":747,"url":22,"identifiers":748},"Puri, 1999, Toxicol Pathol, Development of a recombinant interleukin-4-Pseudomonas exotoxin for therapy of glioblastoma, 53",{},{"id":22,"text":750,"url":22,"identifiers":751},"Quattrocchi, 1999, J Neurooncol, Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas, 141",{},{"id":22,"text":753,"url":22,"identifiers":754},"Rahmathulla, 2013, OncoTargets Ther, Bevacizumab in high-grade gliomas: A review of its uses, toxicity assessment, and future treatment challenges, 371",{},{"id":22,"text":756,"url":22,"identifiers":757},"Rainov, 2000, Hum Gene Ther, A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme, 2389",{},{"id":22,"text":759,"url":22,"identifiers":760},"Rainov, 2000, Gene Ther, Immune response induced by retrovirus-mediated HSV-tk\u002FGCV pharmacogene therapy in patients with glioblastoma multiforme, 1853",{},{"id":22,"text":762,"url":22,"identifiers":763},"Rainov, 2003, J Neurooncol, Clinical trials with retrovirus mediated gene therapy--what have we learned?, 227",{},{"id":22,"text":765,"url":22,"identifiers":766},"Raizer, 2010, Neuro Oncol, A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy, 95",{},{"id":22,"text":768,"url":22,"identifiers":769},"Raizer, 2010, Neuro Oncol, A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas, 87",{},{"id":22,"text":771,"url":22,"identifiers":772},"Ram, 1997, Nat Med, Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells, 1354",{},{"id":22,"text":774,"url":22,"identifiers":775},"Rand, 2000, Clin Cancer Res, Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma, 2157",{},{"id":22,"text":777,"url":22,"identifiers":778},"Raymond, 2008, J Clin Oncol, Phase II study of imatinib in patients with recurrent gliomas of various histologies: A European Organisation for Research and Treatment of Cancer Brain Tumor Group Study, 4659",{},{"id":22,"text":780,"url":22,"identifiers":781},"Reardon, 2009, Br J Cancer, Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma, 1995",{},{"id":22,"text":783,"url":22,"identifiers":784},"Reardon, 2009, Cancer, Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma, 2188",{},{"id":22,"text":786,"url":22,"identifiers":787},"Reardon, 2005, J Clin Oncol, Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme, 9359",{},{"id":22,"text":789,"url":22,"identifiers":790},"Reardon, 2008, J Clin Oncol, Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme, 5610",{},{"id":22,"text":792,"url":22,"identifiers":793},"Reardon, 2008, Expert Opin Investig Drugs, Cilengitide: An integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme, 1225",{},{"id":22,"text":795,"url":22,"identifiers":796},"Reardon, 2011, J Neurooncol, Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma, 621",{},{"id":22,"text":798,"url":22,"identifiers":799},"Reijneveld, 2000, J Neurol, Angiogenesis in malignant primary and metastatic brain tumors, 597",{},{"id":22,"text":801,"url":22,"identifiers":802},"Ricci-Vitiani, 2010, Nature, Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells, 824",{},{"id":22,"text":804,"url":22,"identifiers":805},"Rich, 2004, J Clin Oncol, Phase II trial of gefitinib in recurrent glioblastoma, 133",{},{"id":22,"text":807,"url":22,"identifiers":808},"Riva, 1995, Cancer Res, Local treatment of malignant gliomas by direct infusion of specific monoclonal antibodies labeled with 131I: Comparison of the results obtained in recurrent and newly diagnosed tumors, 5952",{},{"id":22,"text":810,"url":22,"identifiers":811},"Rustamzadeh, 2006, Int J Cancer, Intracranial therapy of glioblastoma with the fusion protein DTIL13 in immunodeficient mice, 2594",{},{"id":22,"text":813,"url":22,"identifiers":814},"Rustamzadeh, 2007, Int J Cancer, Intracranial therapy of glioblastoma with the fusion protein DTAT in immunodeficient mice, 411",{},{"id":22,"text":816,"url":22,"identifiers":817},"Rustamzadeh, 2003, J Neurooncol, Targeting the over-expressed urokinase-type plasminogen activator receptor on glioblastoma multiforme, 63",{},{"id":22,"text":819,"url":22,"identifiers":820},"Rustamzadeh, 2006, J Neurooncol, Immunotoxin pharmacokinetics: A comparison of the anti-glioblastoma bi-specific fusion protein (DTAT13) to DTAT and DTIL13, 257",{},{"id":22,"text":822,"url":22,"identifiers":823},"Sampson, 2003, J Neurooncol, Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors, 27",{},{"id":22,"text":825,"url":22,"identifiers":826},"Sampson, 2008, Semin Immunol, Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma, 267",{},{"id":22,"text":828,"url":22,"identifiers":829},"Sampson, 2009, Mol Cancer Ther, An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme, 2773",{},{"id":22,"text":831,"url":22,"identifiers":832},"Sampson, 2010, J Clin Oncol, Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma, 4722",{},{"id":22,"text":834,"url":22,"identifiers":835},"Sandmair, 2000, Hum Gene Ther, Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses, 2197",{},{"id":22,"text":837,"url":22,"identifiers":838},"Sathornsumetee, 2007, Cancer, Molecularly targeted therapy for malignant glioma, 13",{},{"id":22,"text":840,"url":22,"identifiers":841},"Scaringi, 2012, Anticancer Res, Integrin inhibitor cilengitide for the treatment of glioblastoma: A brief overview of current clinical results, 4213",{},{"id":22,"text":843,"url":22,"identifiers":844},"Schmidt, 1999, Int J Cancer, Levels of vascular endothelial growth factor, hepatocyte growth factor\u002Fscatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis, 10",{},{"id":22,"text":846,"url":22,"identifiers":847},"Schwarzmaier, 2005, J Magn Reson Imaging, MR-guided laser irradiation of recurrent glioblastomas, 799",{},{"id":22,"text":849,"url":22,"identifiers":850},"Schwarzmaier, 2006, Eur J Radiol, MR-guided laser-induced interstitial thermotherapy of recurrent glioblastoma multiforme: Preliminary results in 16 patients, 208",{},{"id":22,"text":852,"url":22,"identifiers":853},"Schwarzmaier, 1998, J Magn Reson Imaging, Treatment planning for MRI-guided laser-induced interstitial thermotherapy of brain tumors--the role of blood perfusion, 121",{},{"id":22,"text":855,"url":22,"identifiers":856},"Sebolt-Leopold, 2004, Nat Rev Cancer, Targeting the mitogen-activated protein kinase cascade to treat cancer, 937",{},{"id":22,"text":858,"url":22,"identifiers":859},"Shah, 2003, J Neurooncol, Oncolytic viruses: Clinical applications as vectors for the treatment of malignant gliomas, 203",{},{"id":22,"text":861,"url":22,"identifiers":862},"Shai, 2003, Oncogene, Gene expression profiling identifies molecular subtypes of gliomas, 4918",{},{"id":22,"text":864,"url":22,"identifiers":865},"Shand, 1999, Hum Gene Ther, A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir.GLI328 European-Canadian Study Group, 2325",{},{"id":22,"text":867,"url":22,"identifiers":868},"Shapiro, 1989, J Neurosurg, Randomized trial of three chemotherapy regimens and two radiotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma.Brain Tumor Cooperative Group Trial 8001, 1",{},{"id":22,"text":870,"url":22,"identifiers":871},"Shaw, 2006, Nature, Ras, PI(3) K and mTOR signalling controls tumour cell growth, 424",{},{"id":22,"text":873,"url":22,"identifiers":874},"Silva, 2008, Arterioscler Thromb Vasc Biol, Integrins: The keys to unlocking angiogenesis, 1703",{},{"id":22,"text":876,"url":22,"identifiers":877},"Singh, 2003, Cancer Res, Identification of a cancer stem cell in human brain tumors, 5821",{},{"id":22,"text":879,"url":22,"identifiers":880},"Singh, 2004, Nature, Identification of human brain tumour initiating cells, 396",{},{"id":22,"text":882,"url":22,"identifiers":883},"Sloan, 2013, J Neurosurg, Results of the NeuroBlate System first-in-humans Phase I clinical trial for recurrent glioblastoma: Clinical article, 1202",{},{"id":22,"text":885,"url":22,"identifiers":886},"Sloan, 2000, Neurosurg Focus, Adoptive immunotherapy in patients with recurrent malignant glioma: Preliminary results of using autologous whole-tumor vaccine plus granulocyte-macrophage colony-stimulating factor and adoptive transfer of anti-CD3-activated lymphocytes, e9",{},{"id":22,"text":888,"url":22,"identifiers":889},"Smitt, 2003, Mol Ther, Treatment of relapsed malignant glioma with an adenoviral vector containing the herpes simplex thymidine kinase gene followed by ganciclovir, 851",{},{"id":22,"text":891,"url":22,"identifiers":892},"Son, 2009, Cell Stem Cell, SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma, 440",{},{"id":22,"text":894,"url":22,"identifiers":895},"Stiles, 2008, Neuron, Glioma stem cells: A midterm exam, 832",{},{"id":22,"text":897,"url":22,"identifiers":898},"Stummer, 2006, Lancet Oncol, Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: A randomised controlled multicentre phase III trial, 392",{},{"id":22,"text":900,"url":22,"identifiers":901},"Stupp R, editor. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma and methylated O6-methylguanine-DNA methyltransferase (MGMT) gene promoter: Key results of the multicenter, randomized, open-label, controlled, phase III CENTRIC study. 2013 ASCO; 2013; Chicago.",{"doi":902},"10.1200\u002Fjco.2013.31.18_suppl.lba2009",{"id":22,"text":904,"url":22,"identifiers":905},"Stupp, 2009, Lancet Oncol, Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial, 459",{},{"id":22,"text":907,"url":22,"identifiers":908},"Stupp, 2010, J Clin Oncol, Phase I\u002FIIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma, 2712",{},{"id":22,"text":910,"url":22,"identifiers":911},"Stupp, 2006, Oncologist, Changing paradigms--an update on the multidisciplinary management of malignant glioma, 165",{},{"id":22,"text":913,"url":22,"identifiers":914},"Stupp, 2005, N Engl J Med, Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma, 987",{},{"id":22,"text":916,"url":22,"identifiers":917},"Sun, 2006, Cancer Cell, Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain, 287",{},{"id":22,"text":919,"url":22,"identifiers":920},"Teicher, 2011, Clin Cancer Res, Antibody conjugate therapeutics: Challenges and potential, 6389",{},{"id":22,"text":922,"url":22,"identifiers":923},"Terada, 2006, Gene Ther, Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models, 705",{},{"id":22,"text":925,"url":22,"identifiers":926},"Thomas, 2012, Cancer J, Immunotherapy for the treatment of glioblastoma, 59",{},{"id":22,"text":928,"url":22,"identifiers":929},"Tobias, 2013, J Neurol Neurosurg Psychiatry, The art of gene therapy for glioma: A review of the challenging road to the bedside, 213",{},{"id":22,"text":931,"url":22,"identifiers":932},"Todhunter, 2004, Protein Eng Des Sel, A bispecific immunotoxin (DTAT13) targeting human IL-13 receptor (IL-13R) and urokinase-type plasminogen activator receptor (uPAR) in a mouse xenograft model, 157",{},{"id":22,"text":934,"url":22,"identifiers":935},"Todo, 2001, Proc Natl Acad Sci U S A, Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing, 6396",{},{"id":22,"text":937,"url":22,"identifiers":938},"Trask, 2000, Mol Ther, Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors, 195",{},{"id":22,"text":940,"url":22,"identifiers":941},"Tsuboi, 2003, Clin Cancer Res, Effects of local injection of ex vivo expanded autologous tumor-specific T lymphocytes in cases with recurrent malignant gliomas, 3294",{},{"id":22,"text":943,"url":22,"identifiers":944},"Tsurushima, 1999, Jpn J Cancer Res, Reduction of end-stage malignant glioma by injection with autologous cytotoxic T lymphocytes, 536",{},{"id":22,"text":946,"url":22,"identifiers":947},"Uhm, 2011, Int J Radiat Oncol Biol Phys, Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo\u002FNorth Central Cancer Treatment Group Study N0074, 347",{},{"id":22,"text":949,"url":22,"identifiers":950},"Ulasov, 2008, J Med Virol, Evaluation of E1A double mutant oncolytic adenovectors in anti-glioma gene therapy, 1595",{},{"id":22,"text":952,"url":22,"identifiers":953},"Ulasov, 2007, Hum Gene Ther, Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma, 589",{},{"id":22,"text":955,"url":22,"identifiers":956},"Vallera, 2002, J Natl Cancer Inst, Targeting urokinase-type plasminogen activator receptor on human glioblastoma tumors with diphtheria toxin fusion protein DTAT, 597",{},{"id":22,"text":958,"url":22,"identifiers":959},"van, 2009, J Clin Oncol, Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034, 1268",{},{"id":22,"text":961,"url":22,"identifiers":962},"van, 2009, J Clin Oncol, MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: A report from EORTC Brain Tumor Group Study 26951, 5881",{},{"id":22,"text":964,"url":22,"identifiers":965},"Van, 2009, Brain Pathol, Dendritic cell therapy of high-grade gliomas, 694",{},{"id":22,"text":967,"url":22,"identifiers":968},"Van, 2004, Semin Oncol, Emerging molecular therapies for brain tumors, 38",{},{"id":22,"text":970,"url":22,"identifiers":971},"Vauleon E, Avril T, Collet B, Mosser J, Quillien V. Overview of cellular immunotherapy for patients with glioblastoma. Clin Dev Immunol 2010;2010.",{"doi":972},"10.1155\u002F2010\u002F689171",{"id":22,"text":974,"url":22,"identifiers":975},"Veeravagu, 2008, Clin Cancer Res, Integrin alphavbeta3-targeted radioimmunotherapy of glioblastoma multiforme, 7330",{},{"id":22,"text":977,"url":22,"identifiers":978},"Verhaak, 2010, Cancer Cell, Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1, 98",{},{"id":22,"text":980,"url":22,"identifiers":981},"Villalva, 2012, Int J Mol Sci, O6-Methylguanine-Methyltransferase (MGMT) promoter methylation status in glioma stem-like cells is correlated to temozolomide sensitivity under differentiation-promoting conditions, 6983",{},{"id":22,"text":983,"url":22,"identifiers":984},"Vredenburgh, 2007, Clin Cancer Res, Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma, 1253",{},{"id":22,"text":986,"url":22,"identifiers":987},"Vredenburgh, 2007, J Clin Oncol, Bevacizumab plus irinotecan in recurrent glioblastoma multiforme, 4722",{},{"id":22,"text":989,"url":22,"identifiers":990},"Vredenburgh, 2012, Int J Radiat Oncol Biol Phys, Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme, 58",{},{"id":22,"text":992,"url":22,"identifiers":993},"Vredenburgh, 2011, Clin Cancer Res, The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma, 4119",{},{"id":22,"text":995,"url":22,"identifiers":996},"Wainwright, 2012, Expert Opin Emerg Drugs, Recent developments on immunotherapy for brain cancer, 181",{},{"id":22,"text":998,"url":22,"identifiers":999},"Wan, 2007, Oncogene, Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism, 1932",{},{"id":22,"text":1001,"url":22,"identifiers":1002},"Wang, 2010, Stem Cells, Notch promotes radioresistance of glioma stem cells, 17",{},{"id":22,"text":1004,"url":22,"identifiers":1005},"Wang, 2010, Nature, Glioblastoma stem-like cells give rise to tumour endothelium, 829",{},{"id":22,"text":1007,"url":22,"identifiers":1008},"Watanabe, 1996, Brain Pathol, Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas, 217",{},{"id":22,"text":1010,"url":22,"identifiers":1011},"Watanabe, 2009, Am J Pathol, IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas, 1149",{},{"id":22,"text":1013,"url":22,"identifiers":1014},"Wen, 2008, N Engl J Med, Malignant gliomas in adults, 492",{},{"id":22,"text":1016,"url":22,"identifiers":1017},"Wen, 2006, Clin Cancer Res, Phase I\u002FII study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08, 4899",{},{"id":22,"text":1019,"url":22,"identifiers":1020},"Westphal, 2003, Neuro Oncol, A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma, 79",{},{"id":22,"text":1022,"url":22,"identifiers":1023},"Wilcox, 2001, J Natl Cancer Inst, Reovirus as an oncolytic agent against experimental human malignant gliomas, 903",{},{"id":22,"text":1025,"url":22,"identifiers":1026},"Wood, 2000, J Neurooncol, A pilot study of autologous cancer cell vaccination and cellular immunotherapy using anti-CD3 stimulated lymphocytes in patients with recurrent grade III\u002FIV astrocytoma, 113",{},{"id":22,"text":1028,"url":22,"identifiers":1029},"Xu, 2012, Clin Dev Immunol, Cellular-based immunotherapies for patients with glioblastoma multiforme, 764213",{},{"id":22,"text":1031,"url":22,"identifiers":1032},"Yajima, 2005, Clin Cancer Res, Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma, 5900",{},{"id":22,"text":1034,"url":22,"identifiers":1035},"Yamamoto, 1994, Cancer Res, Expression and localization of urokinase-type plasminogen activator in human astrocytomas in vivo, 3656",{},{"id":22,"text":1037,"url":22,"identifiers":1038},"Yamanaka, 2008, Trends Mol Med, Cell- and peptide-based immunotherapeutic approaches for glioma, 228",{},{"id":22,"text":1040,"url":22,"identifiers":1041},"Yamanaka, 2003, Br J Cancer, Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: Results of a clinical phase I\u002FII trial, 1172",{},{"id":22,"text":1043,"url":22,"identifiers":1044},"Yan, 2009, N Engl J Med, IDH1 and IDH2 mutations in gliomas, 765",{},{"id":22,"text":1046,"url":22,"identifiers":1047},"Yu, 2004, Cancer Res, Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma, 4973",{},{"id":22,"text":1049,"url":22,"identifiers":1050},"Yu, 2001, Cancer Res, Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration, 842",{},{"id":22,"text":1052,"url":22,"identifiers":1053},"Zhang, 2012, Curr Mol Pharmacol, Temozolomide: Mechanisms of action, repair and resistance, 102",{},{"id":22,"text":1055,"url":22,"identifiers":1056},"Zhao, 2008, Mol Cancer Res, Neural stem cell tropism to glioma: Critical role of tumor hypoxia, 1819",{},false,{"id":1059,"createTime":1060,"updateTime":1060,"relativeEntities":1061,"slug":1062,"properties":1063,"entityType":87,"verifyStatus":88,"verifyTime":1060,"verifyNote":89,"languages":1076,"translateLanguages":22,"viewCount":23,"primaryUrl":1077,"fullTextUrl":22,"authors":1078,"publicationType":147,"publisherRelationship":1096,"citationCount":1132,"citationInfo":1133,"publishDate":199,"publishYear":187,"citationAnalyzeStatus":21,"lastCitationAnalyze":22,"indexDatabases":1142,"openAccess":22,"references":1143,"isForceReanalyzing":1057},"157f221b-74b7-4975-9116-67359e7382ca","2025-01-30T16:41:21.762+00:00",[],"Multidisciplinary-in-hospital-teams-improve-patient-outcomes-A-review",{"openalex":1064,"mag":1066,"title":1068,"pm":1070,"doi":1072,"pmc":1074},{"VOID":1065},"W2019031219",{"VOID":1067},"2019031219",{"EN":1069},"Multidisciplinary in-hospital teams improve patient outcomes: A review",{"VOID":1071},"25289149",{"VOID":1073},"10.4103\u002F2152-7806.139612",{"VOID":1075},"4173201",[91],"http:\u002F\u002Fsurgicalneurologyint.com\u002Fsurgicalint-articles\u002Fmultidisciplinary-in-hospital-teams-improve-patient-outcomes-a-review\u002F",[1079],{"id":1080,"sortIndex":23,"researcher":22,"roles":1081,"affiliations":1082,"properties":1091,"displayName":1093,"givenName":22,"familyName":22},"22863ca3-8aa4-49ef-87de-fd3fb187cfbd",[],[1083],{"id":1084,"sortIndex":23,"affiliation":1085,"properties":22},"614ede8d-3d0e-4ca5-a804-48759cc5cdc3",{"id":1084,"createTime":22,"updateTime":22,"relativeEntities":1086,"slug":22,"properties":1087,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":1090,"statistic":22},[],{"title":1088},{"EN":1089},"Winthrop University Hospital, Chief of Neurosurgical Spine, Education, and Research, Mineola, NY 11501, USA.",[],{"title":1092,"openalex":1094},{"EN":1093},"NancyE Epstein",{"VOID":1095},"A5110510226",{"url":22,"publisher":1097,"properties":1126},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1098,"slug":10,"properties":1099,"entityType":20,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":23,"subjectFields":1103,"manageAffiliations":1112,"indexDatabases":1118,"url":64,"thumbnailPath":22,"statistic":22,"gsStatistic":22,"type":22,"analyzePriority":22},[],{"issn":1100,"title":1101,"country":1102},{"VOID":15},{"EN":17},{"VOID":13},[1104,1108],{"id":26,"createTime":22,"updateTime":22,"relativeEntities":1105,"label":1106,"description":1107,"parentId":22,"standard":22,"scholarHubFieldId":22},[],{"EN":29},{},{"id":32,"createTime":22,"updateTime":22,"relativeEntities":1109,"label":1110,"description":1111,"parentId":22,"standard":22,"scholarHubFieldId":22},[],{"EN":35},{},[1113],{"id":39,"createTime":22,"updateTime":22,"relativeEntities":1114,"slug":22,"properties":1115,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":1117,"statistic":22},[],{"title":1116},{"EN":43},[],[1119],{"id":47,"indexDatabase":1120,"url":58,"indexYears":59,"academicFieldIds":1125,"indexDatabaseRanking":63},{"id":49,"createTime":22,"updateTime":22,"relativeEntities":1121,"label":1122,"description":1123,"key":55,"publicationTags":1124,"standard":22},[],{"EN":52,"VI":52},{"EN":52,"VI":54},[57],[61,62],{"issue":1127,"pages":1129,"volume":1131},{"VOID":1128},"8",{"VOID":1130},"295",{"VOID":184},325,{"total":1132,"publishYear":187,"statisticByYear":1134},{"2015":113,"2016":1135,"2017":1136,"2018":194,"2019":190,"2020":1137,"2021":1138,"2022":1139,"2023":1140,"2024":1141},8,26,55,48,35,41,44,[63],[1144,1147,1150,1153,1156,1159,1162,1165,1168,1171,1174,1177,1180,1183,1187,1190,1193,1196,1199,1202,1205,1208,1212,1215],{"id":22,"text":1145,"url":22,"identifiers":1146},"Adobamen, 2014, Indian J Otolaryngol Head Neck Surg, Ear, nose, throat, head and neck surgery department functioning as a team in Nigeria: Any benefit?, 299",{},{"id":22,"text":1148,"url":22,"identifiers":1149},"Anderson, 2011, Nurs Res, Characterizing the structure of operating room staffing using social network analysis, 378",{},{"id":22,"text":1151,"url":22,"identifiers":1152},"Antoniadis, 2014, J Surg Res, Identification and interference of intraoperative distractions and interruptions in operating rooms, 21",{},{"id":22,"text":1154,"url":22,"identifiers":1155},"Arriaga, 2014, Ann Surg, ; Harvard Surgical Safety Collaborative.Pilot testing of a model for insurer-driven, large-scale multicenter simulation training for operating room teams, 403",{},{"id":22,"text":1157,"url":22,"identifiers":1158},"Ausman, 1999, Surg Neurol, Editorial; The business of surgery: Business principles applied to preoperative planning, operating room management, and surgical strategy, 113",{},{"id":22,"text":1160,"url":22,"identifiers":1161},"Bloos, 2009, Br J Anaesth, Effects of staff training on the care of mechanically ventilated patients: A prospective cohort study, 232",{},{"id":22,"text":1163,"url":22,"identifiers":1164},"D′Amours, 2013, Curr Opin Crit Care, Utility of simultaneous interventional radiology and operative surgery in a dedicated suite for seriously injured patients, 587",{},{"id":22,"text":1166,"url":22,"identifiers":1167},"Estryn-Behar, 2014, J Patient Saf, Shift change handovers and subsequent interruptions: Potential impacts on quality of care, 29",{},{"id":22,"text":1169,"url":22,"identifiers":1170},"Garbee, 2013, Nurs Educ Perspect, Interprofessional teamwork among students in simulated codes: A quasi-experimental study, 339",{},{"id":22,"text":1172,"url":22,"identifiers":1173},"Haugen, 2013, BMC Surg, A survey of surgical team members′ perceptions of near misses and attitudes towards Time Out protocols, 46",{},{"id":22,"text":1175,"url":22,"identifiers":1176},"Hwang, 2014, J Neurosci Nurs, Assessment of satisfaction with care among family members of survivors in a neuroscience intensive care unit, 106",{},{"id":22,"text":1178,"url":22,"identifiers":1179},"Jacobs, 2012, Surg Neurol Int, Consequences and potential problems of operating room outbursts and temper tantrums by surgeons, S167",{},{"id":22,"text":1181,"url":22,"identifiers":1182},"Justic, 2000, Crit Care Nurse, Does \"ICU psychosis\" really exist?, 28",{},{"id":22,"text":1184,"url":22,"identifiers":1185},"Koivunen M, Anttila M, Kuosmanen L, Katajisto J, Välimäki M. Team climate and attitudes toward information and communication technology among nurses on acute psychiatric wards. Inform Health Soc Care 2014 Jan 6. [Epub ahead of print]",{"doi":1186},"10.3109\u002F17538157.2013.872112",{"id":22,"text":1188,"url":22,"identifiers":1189},"Mangum, 2002, AORN J, Increased efficiency through OR redesign and process simplification, 1041",{},{"id":22,"text":1191,"url":22,"identifiers":1192},"McGuinness, 2012, Surg Neurol Int, How to reduce hospital-acquired pressure ulcers on a neuroscience unit with a skin and wound assessment team, 138",{},{"id":22,"text":1194,"url":22,"identifiers":1195},"Overdyk, 1998, Anesth Analg, Successful strategies for improving operating room efficiency at academic institutions, 896",{},{"id":22,"text":1197,"url":22,"identifiers":1198},"Paige, 2014, J Am Coll Surg, Getting a head start: High-fidelity, simulation-based operating room team training of interprofessional students, 140",{},{"id":22,"text":1200,"url":22,"identifiers":1201},"Papaconstantinou, 2013, Ochsner J, Implementation of a surgical safety checklist: Impact on surgical team perspectives, 299",{},{"id":22,"text":1203,"url":22,"identifiers":1204},"Porter, 2014, Jt Comm J Qual Patient Saf, Sustainable, effective implementation of a surgical preprocedural checklist: An \"attestation\" format for all operating team members, 3",{},{"id":22,"text":1206,"url":22,"identifiers":1207},"Pucher, 2014, Surgery, Nontechnical skills performance and care processes in the management of the acute trauma patient, 902",{},{"id":22,"text":1209,"url":22,"identifiers":1210},"Scott JK, Leary SD, Ness AR, Sandy JR, Persson M, Kilpatrick N, et al. Centralization of services for children born with orofacial clefts in the United Kingdom: A cross-sectional survey. Cleft Palate Craniofac J 2014 Feb 7. [Epub ahead of print]",{"doi":1211},"10.1597\u002F13-110",{"id":22,"text":1213,"url":22,"identifiers":1214},"Tsai, 2013, Kaohsiung J Med Sci, Outcomes of the patients in the respiratory care center are not associated with the seniority of the caring resident, 43",{},{"id":22,"text":1216,"url":22,"identifiers":1217},"Williams, 2014, J Crit Care, In-hospital fellow coverage reduces communication errors in the surgical intensive care unit, 445",{},{"id":1219,"createTime":1220,"updateTime":1220,"relativeEntities":1221,"slug":1222,"properties":1223,"entityType":87,"verifyStatus":88,"verifyTime":1220,"verifyNote":89,"languages":1238,"translateLanguages":22,"viewCount":23,"primaryUrl":1239,"fullTextUrl":22,"authors":1240,"publicationType":147,"publisherRelationship":1395,"citationCount":189,"citationInfo":1430,"publishDate":22,"publishYear":22,"citationAnalyzeStatus":21,"lastCitationAnalyze":22,"indexDatabases":1432,"openAccess":22,"references":1433,"isForceReanalyzing":1057},"fb219f31-b152-442b-988d-b34b9d22c0b3","2024-12-29T17:53:40.305+00:00",[],"Surgical-histopathology-of-a-filar-anomaly-as-an-additional-tethering-element-associated-with-closed-spinal-dysraphism-of-primary-neurulation-failure",{"mag":1224,"pmc":1226,"openalex":1228,"abstract":1230,"title":1232,"pm":1234,"doi":1236},{"VOID":1225},"3186082559",{"VOID":1227},"8422463",{"VOID":1229},"W3186082559",{"EN":1231},"\u003Cjats:sec id=\"st1\">\n\u003Cjats:title>Background: \u003C\u002Fjats:title>\n\u003Cjats:p>Closed spinal dysraphism of primary neurulation failure could be associated with filar anomalies, such as filar lipoma or thickened and tight filum terminale (TFT), resulting from impaired secondary neurulation. Retained medullary cord (RMC) is a remnant of the cavitary medullary cord originating from the secondary neurulation failure. Some filar lipomas are known to contain a central canal-like ependyma-lined lumen with surrounding neuroglial tissues (E-LC w\u002FNGT), that is, a characteristic histopathology of RMC. To clarify the embryological background of these filar anomalies, we evaluated the histopathological findings.\u003C\u002Fjats:p>\n\u003C\u002Fjats:sec>\n\u003Cjats:sec id=\"st2\">\n\u003Cjats:title>Methods: \u003C\u002Fjats:title>\n\u003Cjats:p>Among 41 patients with lesions of primary neurulation failure who underwent initial untethering surgery, the filum including cord-like structure (C-LS) was additionally resected in 10 patients (five dorsal and transitional lipomas; five limited dorsal myeloschisis). We retrospectively analyzed the clinical, neuroradiological, intraoperative, and histopathological findings.\u003C\u002Fjats:p>\n\u003C\u002Fjats:sec>\n\u003Cjats:sec id=\"st3\">\n\u003Cjats:title>Results: \u003C\u002Fjats:title>\n\u003Cjats:p>Among 10 patients, two patients were diagnosed with RMC based on morphological features and intraoperative neurophysiological monitoring. The diagnosis of filar lipoma was made in six patients, since various amounts of fibroadipose tissue were histopathologically noted in the filum. Two patients were diagnosed with TFT, since the filum was composed solely of fibrocollagenous tissue. E-LC w\u002FNGT was noted not only in both C-LSs of RMCs but also in two out of six fila both with filar lipomas and fila with TFTs.\u003C\u002Fjats:p>\n\u003C\u002Fjats:sec>\n\u003Cjats:sec id=\"st4\">\n\u003Cjats:title>Conclusion: \u003C\u002Fjats:title>\n\u003Cjats:p>These findings provide further evidence for the idea that entities, such as filar lipoma, TFT, and RMC, can be considered consequences of a continuum of regression failure occurring during late secondary neurulation.\u003C\u002Fjats:p>\n\u003C\u002Fjats:sec>",{"EN":1233},"Surgical histopathology of a filar anomaly as an additional tethering element associated with closed spinal dysraphism of primary neurulation failure",{"VOID":1235},"34513140",{"VOID":1237},"10.25259\u002Fsni_340_2021",[91],"http:\u002F\u002Fsurgicalneurologyint.com\u002Fsurgicalint-articles\u002Fsurgical-histopathology-of-a-filar-anomaly-as-an-additional-tethering-element-associated-with-closed-spinal-dysraphism-of-primary-neurulation-failure\u002F",[1241,1268,1285,1304,1324,1344,1362,1378],{"id":1242,"sortIndex":23,"researcher":22,"roles":1243,"affiliations":1244,"properties":1261,"displayName":1265,"givenName":22,"familyName":22},"4d4de1c0-f48f-4c08-8f54-133d92fd304e",[],[1245,1253],{"id":1246,"sortIndex":23,"affiliation":1247,"properties":22},"4ddd89c1-3f20-4e5d-8137-67e4c96c0c4a",{"id":1246,"createTime":22,"updateTime":22,"relativeEntities":1248,"slug":22,"properties":1249,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":1252,"statistic":22},[],{"title":1250},{"VI":1251},"Department of Neurosurgery, Fukuoka Children’s Hospital, Fukuoka, Japan",[],{"id":1254,"sortIndex":113,"affiliation":1255,"properties":22},"8ce5d1b3-c6d4-4299-b1e5-18aebdfeb547",{"id":1254,"createTime":22,"updateTime":22,"relativeEntities":1256,"slug":22,"properties":1257,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":1260,"statistic":22},[],{"title":1258},{"EN":1259},"Department of Neurosurgery, Harasanshin Hospital, Karatsu, Saga,",[],{"orcid":1262,"title":1264,"openalex":1266},{"VOID":1263},"https:\u002F\u002Forcid.org\u002F0000-0003-2114-2756",{"EN":1265},"Takato Morioka",{"VOID":1267},"A5087781499",{"id":1269,"sortIndex":113,"researcher":22,"roles":1270,"affiliations":1271,"properties":1278,"displayName":1282,"givenName":22,"familyName":22},"424f6a63-80e9-4607-9902-72fcc01edc78",[],[1272],{"id":1246,"sortIndex":23,"affiliation":1273,"properties":22},{"id":1246,"createTime":22,"updateTime":22,"relativeEntities":1274,"slug":22,"properties":1275,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":1277,"statistic":22},[],{"title":1276},{"VI":1251},[],{"orcid":1279,"title":1281,"openalex":1283},{"VOID":1280},"https:\u002F\u002Forcid.org\u002F0000-0002-6177-1680",{"EN":1282},"Nobuya Murakami",{"VOID":1284},"A5041594249",{"id":1286,"sortIndex":129,"researcher":22,"roles":1287,"affiliations":1288,"properties":1297,"displayName":1301,"givenName":22,"familyName":22},"2953e25a-6271-44c9-9071-918cd4631071",[],[1289],{"id":1290,"sortIndex":23,"affiliation":1291,"properties":22},"803e72e2-10fe-479e-8b00-0e30a906fed8",{"id":1290,"createTime":22,"updateTime":22,"relativeEntities":1292,"slug":22,"properties":1293,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":1296,"statistic":22},[],{"title":1294},{"EN":1295},"Department of Psychiatry, Shourai Hospital, Karatsu, Saga,",[],{"orcid":1298,"title":1300,"openalex":1302},{"VOID":1299},"https:\u002F\u002Forcid.org\u002F0000-0002-1977-2698",{"EN":1301},"Satoshi Suzuki",{"VOID":1303},"A5032413419",{"id":1305,"sortIndex":1306,"researcher":22,"roles":1307,"affiliations":1308,"properties":1317,"displayName":1321,"givenName":22,"familyName":22},"c8fe2c0d-d24e-41bd-9c30-eefa15abe5ba",3,[],[1309],{"id":1310,"sortIndex":23,"affiliation":1311,"properties":22},"c6450c74-7028-4bf1-b93e-f5d9e8e5bfc7",{"id":1310,"createTime":22,"updateTime":22,"relativeEntities":1312,"slug":22,"properties":1313,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":1316,"statistic":22},[],{"title":1314},{"EN":1315},"Department of Neurosurgery, Graduate School of Medical Sciences, Fukuoka, Japan.",[],{"orcid":1318,"title":1320,"openalex":1322},{"VOID":1319},"https:\u002F\u002Forcid.org\u002F0000-0003-1990-1485",{"EN":1321},"Nobutaka Mukae",{"VOID":1323},"A5060269926",{"id":1325,"sortIndex":1326,"researcher":22,"roles":1327,"affiliations":1328,"properties":1337,"displayName":1341,"givenName":22,"familyName":22},"dcf204ef-1947-421a-bef1-03a8f6b9b057",4,[],[1329],{"id":1330,"sortIndex":23,"affiliation":1331,"properties":22},"11401bcb-d9f0-482d-b151-278b5b688c94",{"id":1330,"createTime":22,"updateTime":22,"relativeEntities":1332,"slug":22,"properties":1333,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":1336,"statistic":22},[],{"title":1334},{"EN":1335},"Department of Neurosurgery, Kyushu University, Fukuoka, Fukuoka, Japan.",[],{"orcid":1338,"title":1340,"openalex":1342},{"VOID":1339},"https:\u002F\u002Forcid.org\u002F0000-0002-1116-7194",{"EN":1341},"Takafumi Shimogawa",{"VOID":1343},"A5076462619",{"id":1345,"sortIndex":1346,"researcher":22,"roles":1347,"affiliations":1348,"properties":1355,"displayName":1359,"givenName":22,"familyName":22},"ab1af80d-8fee-4dc2-9351-5eb61cb9141a",5,[],[1349],{"id":1246,"sortIndex":23,"affiliation":1350,"properties":22},{"id":1246,"createTime":22,"updateTime":22,"relativeEntities":1351,"slug":22,"properties":1352,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":1354,"statistic":22},[],{"title":1353},{"VI":1251},[],{"orcid":1356,"title":1358,"openalex":1360},{"VOID":1357},"https:\u002F\u002Forcid.org\u002F0000-0002-2740-0990",{"EN":1359},"Ai Kurogi",{"VOID":1361},"A5019090516",{"id":1363,"sortIndex":1364,"researcher":22,"roles":1365,"affiliations":1366,"properties":1373,"displayName":1375,"givenName":22,"familyName":22},"f962e220-bcfc-4490-9b98-70edd81fffa6",6,[],[1367],{"id":1254,"sortIndex":23,"affiliation":1368,"properties":22},{"id":1254,"createTime":22,"updateTime":22,"relativeEntities":1369,"slug":22,"properties":1370,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":1372,"statistic":22},[],{"title":1371},{"EN":1259},[],{"title":1374,"openalex":1376},{"EN":1375},"Tadahisa Shono",{"VOID":1377},"A5102429677",{"id":1379,"sortIndex":189,"researcher":22,"roles":1380,"affiliations":1381,"properties":1388,"displayName":1392,"givenName":22,"familyName":22},"3e608d37-14a3-4d1e-b8a8-45064a29cf34",[],[1382],{"id":1310,"sortIndex":23,"affiliation":1383,"properties":22},{"id":1310,"createTime":22,"updateTime":22,"relativeEntities":1384,"slug":22,"properties":1385,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":1387,"statistic":22},[],{"title":1386},{"EN":1315},[],{"orcid":1389,"title":1391,"openalex":1393},{"VOID":1390},"https:\u002F\u002Forcid.org\u002F0000-0001-7690-2586",{"EN":1392},"Masahiro Mizoguchi",{"VOID":1394},"A5101665949",{"url":22,"publisher":1396,"properties":1425},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1397,"slug":10,"properties":1398,"entityType":20,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":23,"subjectFields":1402,"manageAffiliations":1411,"indexDatabases":1417,"url":64,"thumbnailPath":22,"statistic":22,"gsStatistic":22,"type":22,"analyzePriority":22},[],{"issn":1399,"title":1400,"country":1401},{"VOID":15},{"EN":17},{"VOID":13},[1403,1407],{"id":26,"createTime":22,"updateTime":22,"relativeEntities":1404,"label":1405,"description":1406,"parentId":22,"standard":22,"scholarHubFieldId":22},[],{"EN":29},{},{"id":32,"createTime":22,"updateTime":22,"relativeEntities":1408,"label":1409,"description":1410,"parentId":22,"standard":22,"scholarHubFieldId":22},[],{"EN":35},{},[1412],{"id":39,"createTime":22,"updateTime":22,"relativeEntities":1413,"slug":22,"properties":1414,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":1416,"statistic":22},[],{"title":1415},{"EN":43},[],[1418],{"id":47,"indexDatabase":1419,"url":58,"indexYears":59,"academicFieldIds":1424,"indexDatabaseRanking":63},{"id":49,"createTime":22,"updateTime":22,"relativeEntities":1420,"label":1421,"description":1422,"key":55,"publicationTags":1423,"standard":22},[],{"EN":52,"VI":52},{"EN":52,"VI":54},[57],[61,62],{"pages":1426,"volume":1428},{"VOID":1427},"373",{"VOID":1429},"12",{"total":189,"publishYear":22,"statisticByYear":1431},{"2021":113,"2022":129,"2023":129,"2024":129},[],[1434,1438,1442,1446,1450,1453,1457,1461,1465,1469,1473,1477,1481,1485,1489,1493,1497,1501,1505,1509,1513,1517,1521,1525,1529],{"id":22,"text":1435,"url":22,"identifiers":1436},"Arai, 2001, Surgical experience of 120 patients with lumbosacral lipomas, Acta Neurochir (Wien), 143, 857, 10.1007\u002Fs007010170015",{"doi":1437},"10.1007\u002Fs007010170015",{"id":22,"text":1439,"url":22,"identifiers":1440},"Choi, 2019, The ventriculus terminalis and filum terminate of the human spinal cord, Hum Pathol, 23, 916, 10.1016\u002F0046-8177(92)90405-R",{"doi":1441},"10.1016\u002F0046-8177(92)90405-R",{"id":22,"text":1443,"url":22,"identifiers":1444},"Durdaĝ, 2015, Pathological evaluation of the filum terminale tissue after surgical excision, Childs Nerv Syst, 31, 759, 10.1007\u002Fs00381-015-2627-4",{"doi":1445},"10.1007\u002Fs00381-015-2627-4",{"id":22,"text":1447,"url":22,"identifiers":1448},"Gupta, 2018, Fatty filum terminale (FFT) as a secondary tethering element in children with closed spinal dysraphism, Childs Nerv Syst, 34, 925, 10.1007\u002Fs00381-017-3700-y",{"doi":1449},"10.1007\u002Fs00381-017-3700-y",{"id":22,"text":1451,"url":22,"identifiers":1452},"Hashiguchi, 2005, Usefulness of constructive interference in steady-state magnetic resonance imaging in the presurgical examination for lumbosacral lipoma, J Neurosurg, 103, 537",{},{"id":22,"text":1454,"url":22,"identifiers":1455},"Hiraoka, 2018, Limited dorsal myeloschisis with no extradural stalk linking to a flat skin lesion: A case report, Childs Nerv Syst, 34, 2497, 10.1007\u002Fs00381-018-3938-z",{"doi":1456},"10.1007\u002Fs00381-018-3938-z",{"id":22,"text":1458,"url":22,"identifiers":1459},"Kim, 2020, Secondary neurulation defects-1: Retained medullary cord, J Korean Neurosurg Soc, 63, 314, 10.3340\u002Fjkns.2020.0052",{"doi":1460},"10.3340\u002Fjkns.2020.0052",{"id":22,"text":1462,"url":22,"identifiers":1463},"Kurogi, 2021, Two cases of retained medullary cord running parallel to a terminal lipoma, Surg Neurol Int, 12, 112, 10.25259\u002FSNI_626_2020",{"doi":1464},"10.25259\u002FSNI_626_2020",{"id":22,"text":1466,"url":22,"identifiers":1467},"Morioka, 2020, Congenital dermal sinus elements in each tethering stalk of coexisting thoracic limited dorsal myeloschisis and retained medullary cord, Pediatr Neurosurg, 55, 380, 10.1159\u002F000511876",{"doi":1468},"10.1159\u002F000511876",{"id":22,"text":1470,"url":22,"identifiers":1471},"Morioka, 2020, Retained medullary cord associated with sacral subcutaneous meningocele and congenital dermal sinus, Childs Nerv Syst, 36, 423, 10.1007\u002Fs00381-019-04301-1",{"doi":1472},"10.1007\u002Fs00381-019-04301-1",{"id":22,"text":1474,"url":22,"identifiers":1475},"Morioka, 2017, Neurosurgical management and pathology of lumbosacral lipomas with tethered cord, Neuropathology, 37, 385, 10.1111\u002Fneup.12382",{"doi":1476},"10.1111\u002Fneup.12382",{"id":22,"text":1478,"url":22,"identifiers":1479},"Morioka, 2020, Terminal syringomyelia associated with lumbar limited dorsal myeloschisis, Childs Nerv Syst, 36, 819, 10.1007\u002Fs00381-019-04297-8",{"doi":1480},"10.1007\u002Fs00381-019-04297-8",{"id":22,"text":1482,"url":22,"identifiers":1483},"Morioka, 2019, Surgical histopathology of limited dorsal myeloschisis with flat skin lesion, Childs Nerv Syst, 35, 119, 10.1007\u002Fs00381-018-3870-2",{"doi":1484},"10.1007\u002Fs00381-018-3870-2",{"id":22,"text":1486,"url":22,"identifiers":1487},"Morioka, 2018, Neurosurgical pathology of limited dorsal myeloschisis, Childs Nerv Syst, 34, 293, 10.1007\u002Fs00381-017-3625-5",{"doi":1488},"10.1007\u002Fs00381-017-3625-5",{"id":22,"text":1490,"url":22,"identifiers":1491},"Morota, 2017, New classification of spinal lipomas based on embryonic stage, J Neurosurg Pediatr, 19, 428, 10.3171\u002F2016.10.PEDS16247",{"doi":1492},"10.3171\u002F2016.10.PEDS16247",{"id":22,"text":1494,"url":22,"identifiers":1495},"Mukae, 2020, Two cases of large filar cyst associated with terminal lipoma: Relationship with retained medullary cord, World Neurosug, 142, 294, 10.1016\u002Fj.wneu.2020.07.026",{"doi":1496},"10.1016\u002Fj.wneu.2020.07.026",{"id":22,"text":1498,"url":22,"identifiers":1499},"Murakami, 2013, Usefulness of three-dimensional T1-weighted spoiled gradient-recalled echo and three-dimensional heavily T2-weighted images in preoperative evaluation of spinal dysraphism, Childs Nerv Syst, 29, 1905, 10.1007\u002Fs00381-013-2140-6",{"doi":1500},"10.1007\u002Fs00381-013-2140-6",{"id":22,"text":1502,"url":22,"identifiers":1503},"Murakami, 2018, Retained medullary cord extending to a sacral subcutaneous menigocele, Childs Nerv Syst, 34, 527, 10.1007\u002Fs00381-017-3644-2",{"doi":1504},"10.1007\u002Fs00381-017-3644-2",{"id":22,"text":1506,"url":22,"identifiers":1507},"Murakami, 2018, Ependyma-lined canal with surrounding neuroglial tissues in lumboscaral lipomatous malformations: Relationship with retained medullary cord, Pediatr Neurosurg, 53, 387, 10.1159\u002F000494029",{"doi":1508},"10.1159\u002F000494029",{"id":22,"text":1510,"url":22,"identifiers":1511},"Pang, 2020, Secondary neurulation defects-1: Thickened filum terminale, retained medullary cord, Textbook of Pediatric Neurosurgery, 1st ed, 10.1007\u002F978-3-319-72168-2_112",{"doi":1512},"10.1007\u002F978-3-319-72168-2_112",{"id":22,"text":1514,"url":22,"identifiers":1515},"Pang, 2011, Retained medullary cord in humans: Late arrest of secondary neurulation, Neurosurgery, 68, 1500, 10.1227\u002FNEU.0b013e31820ee282",{"doi":1516},"10.1227\u002FNEU.0b013e31820ee282",{"id":22,"text":1518,"url":22,"identifiers":1519},"Pang, 1993, Sacral agenesis and caudal spinal cord malformations, Neurosurgery, 32, 755, 10.1227\u002F00006123-199305000-00009",{"doi":1520},"10.1227\u002F00006123-199305000-00009",{"id":22,"text":1522,"url":22,"identifiers":1523},"Sala, 2014, Retained medullary cord confirmed by intraoperative neurophysiological mapping, Childs Nerv Syst, 30, 1287, 10.1007\u002Fs00381-014-2372-0",{"doi":1524},"10.1007\u002Fs00381-014-2372-0",{"id":22,"text":1526,"url":22,"identifiers":1527},"Selçuki, 2003, Is a filum terminale with a normal appearance rarely normal?, Childs Nerv Syst, 19, 3, 10.1007\u002Fs00381-002-0665-1",{"doi":1528},"10.1007\u002Fs00381-002-0665-1",{"id":22,"text":1530,"url":22,"identifiers":1531},"Shirozu, 2018, Enlargement of sacral subcutaneous meningocele associated with retained medullary cord, Childs Nerv Syst, 34, 1785, 10.1007\u002Fs00381-018-3812-z",{"doi":1532},"10.1007\u002Fs00381-018-3812-z",{"id":1534,"createTime":1535,"updateTime":1535,"relativeEntities":1536,"slug":1537,"properties":1538,"entityType":87,"verifyStatus":88,"verifyTime":1535,"verifyNote":89,"languages":1553,"translateLanguages":22,"viewCount":23,"primaryUrl":1554,"fullTextUrl":22,"authors":1555,"publicationType":147,"publisherRelationship":1679,"citationCount":1135,"citationInfo":1713,"publishDate":22,"publishYear":22,"citationAnalyzeStatus":21,"lastCitationAnalyze":22,"indexDatabases":1715,"openAccess":22,"references":1716,"isForceReanalyzing":1057},"90a08793-ee60-4f91-955f-ecc8ab9d4cd4","2024-12-29T17:53:39.502+00:00",[],"Two-cases-of-retained-medullary-cord-running-parallel-to-a-terminal-lipoma",{"mag":1539,"pmc":1541,"openalex":1543,"abstract":1545,"title":1547,"pm":1549,"doi":1551},{"VOID":1540},"3136265787",{"VOID":1542},"8053431",{"VOID":1544},"W3136265787",{"EN":1546},"\u003Cjats:sec id=\"st1\">\n\u003Cjats:title>Background: \u003C\u002Fjats:title>\n\u003Cjats:p>Retained medullary cord (RMC) is a newly defined entity believed to originate from the late arrest of secondary neurulation. Some RMCs contain varying amounts of lipomatous tissues, which need to be differentiated from spinal lipomas, such as filar and caudal lipomas (terminal lipomas).\u003C\u002Fjats:p>\n\u003C\u002Fjats:sec>\n\u003Cjats:sec id=\"st2\">\n\u003Cjats:title>Case Description: \u003C\u002Fjats:title>\n\u003Cjats:p>We surgically treated two patients with a nonfunctional cord-like structure (C-LS) that was continuous from the cord and extended to the dural cul-de-sac, and ran parallel to the terminal lipoma. In both cases, untethering surgery was performed by resecting the C-LS with lipoma as a column, under intraoperative neurophysiological monitoring. Histopathological examination confirmed that the central canal-like ependyma-lined lumen with surrounding neuroglial and fibrocollagenous tissues, which is the central histopathological feature of an RMC, was located on the unilateral side of the resected column, while the fibroadipose tissues of the lipoma were located on the contralateral side.\u003C\u002Fjats:p>\n\u003C\u002Fjats:sec>\n\u003Cjats:sec id=\"st3\">\n\u003Cjats:title>Conclusion: \u003C\u002Fjats:title>\n\u003Cjats:p>Our findings support the idea proposed by Pang \u003Cjats:italic>et al\u003C\u002Fjats:italic>. that entities such as RMC and terminal lipomas are members of a continuum of regression failure occurring during late secondary neurulation, and the coexistence of RMC and terminal lipoma is not a surprising finding. Therefore, it may be difficult in clinical practice to make a distinct diagnosis between these two entities.\u003C\u002Fjats:p>\n\u003C\u002Fjats:sec>",{"EN":1548},"Two cases of retained medullary cord running parallel to a terminal lipoma",{"VOID":1550},"33880217",{"VOID":1552},"10.25259\u002Fsni_626_2020",[91],"http:\u002F\u002Fsurgicalneurologyint.com\u002Fsurgicalint-articles\u002Ftwo-cases-of-retained-medullary-cord-running-parallel-to-a-terminal-lipoma\u002F",[1556,1572,1586,1602,1618,1632,1649,1665],{"id":1557,"sortIndex":23,"researcher":22,"roles":1558,"affiliations":1559,"properties":1568,"displayName":1359,"givenName":22,"familyName":22},"1d731b80-3c5e-4ce9-8839-8f724d744728",[],[1560],{"id":1561,"sortIndex":23,"affiliation":1562,"properties":22},"07d9f616-0746-40f3-a9f0-2f84ef0bc30b",{"id":1561,"createTime":22,"updateTime":22,"relativeEntities":1563,"slug":22,"properties":1564,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":1567,"statistic":22},[],{"title":1565},{"EN":1566},"Department of Neurosurgery, Fukuoka Children’s Hospital, Saga, Japan.",[],{"orcid":1569,"title":1570,"openalex":1571},{"VOID":1357},{"EN":1359},{"VOID":1361},{"id":1573,"sortIndex":113,"researcher":22,"roles":1574,"affiliations":1575,"properties":1582,"displayName":1282,"givenName":22,"familyName":22},"b06ebaba-19e6-4266-a198-38f36585836b",[],[1576],{"id":1561,"sortIndex":23,"affiliation":1577,"properties":22},{"id":1561,"createTime":22,"updateTime":22,"relativeEntities":1578,"slug":22,"properties":1579,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":1581,"statistic":22},[],{"title":1580},{"EN":1566},[],{"orcid":1583,"title":1584,"openalex":1585},{"VOID":1280},{"EN":1282},{"VOID":1284},{"id":1587,"sortIndex":129,"researcher":22,"roles":1588,"affiliations":1589,"properties":1598,"displayName":1265,"givenName":22,"familyName":22},"26188dac-bfa9-42d8-895a-85d5dd78c15b",[],[1590],{"id":1591,"sortIndex":23,"affiliation":1592,"properties":22},"4da77003-818e-4e0d-889c-c3a9635e307f",{"id":1591,"createTime":22,"updateTime":22,"relativeEntities":1593,"slug":22,"properties":1594,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":1597,"statistic":22},[],{"title":1595},{"EN":1596},"Department of Neurosurgery, Harasanshin Hospital, Saga, Japan.",[],{"orcid":1599,"title":1600,"openalex":1601},{"VOID":1263},{"EN":1265},{"VOID":1267},{"id":1603,"sortIndex":1306,"researcher":22,"roles":1604,"affiliations":1605,"properties":1614,"displayName":1321,"givenName":22,"familyName":22},"63e77e23-45f3-45f3-9e27-f81492dde8c8",[],[1606],{"id":1607,"sortIndex":23,"affiliation":1608,"properties":22},"ba47879a-b939-4984-a381-b89e5ae16d35",{"id":1607,"createTime":22,"updateTime":22,"relativeEntities":1609,"slug":22,"properties":1610,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":1613,"statistic":22},[],{"title":1611},{"EN":1612},"Department of Neurosurgery, Kyushu University, Saga, Japan.",[],{"orcid":1615,"title":1616,"openalex":1617},{"VOID":1319},{"EN":1321},{"VOID":1323},{"id":1619,"sortIndex":1326,"researcher":22,"roles":1620,"affiliations":1621,"properties":1628,"displayName":1341,"givenName":22,"familyName":22},"cc4210e3-15f1-4c24-9d38-4bde5daa9520",[],[1622],{"id":1607,"sortIndex":23,"affiliation":1623,"properties":22},{"id":1607,"createTime":22,"updateTime":22,"relativeEntities":1624,"slug":22,"properties":1625,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":1627,"statistic":22},[],{"title":1626},{"EN":1612},[],{"orcid":1629,"title":1630,"openalex":1631},{"VOID":1339},{"EN":1341},{"VOID":1343},{"id":1633,"sortIndex":1346,"researcher":22,"roles":1634,"affiliations":1635,"properties":1644,"displayName":1646,"givenName":22,"familyName":22},"8f2adf6f-a2f9-438b-a903-866c0783f5c3",[],[1636],{"id":1637,"sortIndex":23,"affiliation":1638,"properties":22},"a674ff99-82eb-4675-9151-97728635c1ae",{"id":1637,"createTime":22,"updateTime":22,"relativeEntities":1639,"slug":22,"properties":1640,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":1643,"statistic":22},[],{"title":1641},{"EN":1642},"Department of Dermatology, Fukuoka Children’s Hospital, Saga, Japan.",[],{"title":1645,"openalex":1647},{"EN":1646},"Kyoko Kudo",{"VOID":1648},"A5111533140",{"id":1650,"sortIndex":1364,"researcher":22,"roles":1651,"affiliations":1652,"properties":1661,"displayName":1301,"givenName":22,"familyName":22},"93e4dd1a-6a70-469a-a926-3a4705e6be98",[],[1653],{"id":1654,"sortIndex":23,"affiliation":1655,"properties":22},"2dc177f9-c7d9-45fc-8ecc-95be5d50c975",{"id":1654,"createTime":22,"updateTime":22,"relativeEntities":1656,"slug":22,"properties":1657,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":1660,"statistic":22},[],{"title":1658},{"EN":1659},"Department of Psychiatry, Shourai Hospital, Saga, Japan.",[],{"orcid":1662,"title":1663,"openalex":1664},{"VOID":1299},{"EN":1301},{"VOID":1303},{"id":1666,"sortIndex":189,"researcher":22,"roles":1667,"affiliations":1668,"properties":1675,"displayName":1392,"givenName":22,"familyName":22},"b5519a35-b56b-440c-a01e-93430923416e",[],[1669],{"id":1607,"sortIndex":23,"affiliation":1670,"properties":22},{"id":1607,"createTime":22,"updateTime":22,"relativeEntities":1671,"slug":22,"properties":1672,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":1674,"statistic":22},[],{"title":1673},{"EN":1612},[],{"orcid":1676,"title":1677,"openalex":1678},{"VOID":1390},{"EN":1392},{"VOID":1394},{"url":22,"publisher":1680,"properties":1709},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1681,"slug":10,"properties":1682,"entityType":20,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":23,"subjectFields":1686,"manageAffiliations":1695,"indexDatabases":1701,"url":64,"thumbnailPath":22,"statistic":22,"gsStatistic":22,"type":22,"analyzePriority":22},[],{"issn":1683,"title":1684,"country":1685},{"VOID":15},{"EN":17},{"VOID":13},[1687,1691],{"id":26,"createTime":22,"updateTime":22,"relativeEntities":1688,"label":1689,"description":1690,"parentId":22,"standard":22,"scholarHubFieldId":22},[],{"EN":29},{},{"id":32,"createTime":22,"updateTime":22,"relativeEntities":1692,"label":1693,"description":1694,"parentId":22,"standard":22,"scholarHubFieldId":22},[],{"EN":35},{},[1696],{"id":39,"createTime":22,"updateTime":22,"relativeEntities":1697,"slug":22,"properties":1698,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":1700,"statistic":22},[],{"title":1699},{"EN":43},[],[1702],{"id":47,"indexDatabase":1703,"url":58,"indexYears":59,"academicFieldIds":1708,"indexDatabaseRanking":63},{"id":49,"createTime":22,"updateTime":22,"relativeEntities":1704,"label":1705,"description":1706,"key":55,"publicationTags":1707,"standard":22},[],{"EN":52,"VI":52},{"EN":52,"VI":54},[57],[61,62],{"pages":1710,"volume":1712},{"VOID":1711},"112",{"VOID":1429},{"total":1135,"publishYear":22,"statisticByYear":1714},{"2021":129,"2022":1306,"2023":129,"2024":113},[],[1717,1719,1723,1726,1728,1731,1734,1737,1739,1741,1743],{"id":22,"text":1458,"url":22,"identifiers":1718},{"doi":1460},{"id":22,"text":1720,"url":22,"identifiers":1721},"Morioka, 2007, Dynamic morphological changes in lumbosacral lipoma during the first months of life revealed by constructive interference in steady-state (CISS) MR imaging, Child Nerve Syst, 23, 415, 10.1007\u002Fs00381-006-0272-7",{"doi":1722},"10.1007\u002Fs00381-006-0272-7",{"id":22,"text":1724,"url":22,"identifiers":1725},"Morioka, 2020, Retained medullary cord with sacral subcutaneous meningocele and congenital dermal sinus, Childs Nerv Syst, 36, 423, 10.1007\u002Fs00381-019-04301-1",{"doi":1472},{"id":22,"text":1490,"url":22,"identifiers":1727},{"doi":1492},{"id":22,"text":1729,"url":22,"identifiers":1730},"Mukae, 2020, Two cases of large filar cyst associated with terminal lipoma: Relationship with retained medullary cord, World Neurosurg, 142, 294, 10.1016\u002Fj.wneu.2020.07.026",{"doi":1496},{"id":22,"text":1732,"url":22,"identifiers":1733},"Murakami, 2018, Retained medullary cord extending to a sacral subcutaneous meningocele, Childs Nerv Syst, 34, 527, 10.1007\u002Fs00381-017-3644-2",{"doi":1504},{"id":22,"text":1735,"url":22,"identifiers":1736},"Murakami, 2018, Ependyma-lined canal with surrounding neuroglial tissues in lumbosacral lipomatous malformations: Relationship with retained medullary cord, Pediatr Neurosurg, 53, 387, 10.1159\u002F000494029",{"doi":1508},{"id":22,"text":1510,"url":22,"identifiers":1738},{"doi":1512},{"id":22,"text":1514,"url":22,"identifiers":1740},{"doi":1516},{"id":22,"text":1522,"url":22,"identifiers":1742},{"doi":1524},{"id":22,"text":1530,"url":22,"identifiers":1744},{"doi":1532},{"id":1746,"createTime":1747,"updateTime":1747,"relativeEntities":1748,"slug":1749,"properties":1750,"entityType":87,"verifyStatus":88,"verifyTime":1747,"verifyNote":89,"languages":1765,"translateLanguages":22,"viewCount":23,"primaryUrl":1766,"fullTextUrl":22,"authors":1767,"publicationType":147,"publisherRelationship":1889,"citationCount":1924,"citationInfo":1925,"publishDate":22,"publishYear":22,"citationAnalyzeStatus":21,"lastCitationAnalyze":22,"indexDatabases":1927,"openAccess":22,"references":1928,"isForceReanalyzing":1057},"071ebb9b-8de7-4854-b100-35b6b9c591da","2024-12-10T10:08:07.514+00:00",[],"Prolonged-length-of-stay-and-discharge-disposition-to-rehabilitation-facilities-following-single-level-posterior-lumbar-interbody-fusion-for-acquired-spondylolisthesis",{"mag":1751,"pmc":1753,"openalex":1755,"abstract":1757,"title":1759,"pm":1761,"doi":1763},{"VOID":1752},"3108902919",{"VOID":1754},"7749969",{"VOID":1756},"W3108902919",{"EN":1758},"\u003Cjats:sec id=\"st1\">\n\u003Cjats:title>Background: \u003C\u002Fjats:title>\n\u003Cjats:p>Acquired lumbar spondylolisthesis is often treated with interbody fusion. However, few studies have evaluated predictors for prolonged length of stay (LOS) and disposition to rehabilitation facilities after posterior single-level lumbar interbody fusion for acquired spondylolisthesis.\u003C\u002Fjats:p>\n\u003C\u002Fjats:sec>\n\u003Cjats:sec id=\"st2\">\n\u003Cjats:title>Methods: \u003C\u002Fjats:title>\n\u003Cjats:p>The American College of Surgeons National Quality Improvement Program database was queried for adults with acquired spondylolisthesis who underwent single-level lumbar interbody fusion through a posterior approach (posterior lumbar interbody fusion (PLIF) or transforaminal lumbar interbody fusion [TLIF]). We utilized multivariate logistic regression analysis to identify predictors of prolonged LOS and disposition in this patient population.\u003C\u002Fjats:p>\n\u003C\u002Fjats:sec>\n\u003Cjats:sec id=\"st3\">\n\u003Cjats:title>Results: \u003C\u002Fjats:title>\n\u003Cjats:p>Among 2080 patients identified, 700 (33.7%) had a prolonged LOS (≥4 days), and 306 (14.7%) were discharged postoperatively to rehabilitation facilities. Predictors for prolonged LOS included: American Society of Anesthesiologist (ASA) class ≥3, anemia, prolonged operative time, perioperative blood transfusion, pneumonia, urinary tract infections, and return to the operating room. The following risk factors predicted discharge to postoperative rehabilitation facilities: age ≥65 years, male sex, ASA class ≥3, modified frailty score ≥2, perioperative blood transfusion, and prolonged LOS.\u003C\u002Fjats:p>\n\u003C\u002Fjats:sec>\n\u003Cjats:sec id=\"st4\">\n\u003Cjats:title>Conclusion: \u003C\u002Fjats:title>\n\u003Cjats:p>Multiple partial-overlapping risk factors predicted prolonged LOS and discharge to rehabilitation facilities after single-level TLIF\u002FPLIF performed for acquired spondylolisthesis.\u003C\u002Fjats:p>\n\u003C\u002Fjats:sec>",{"EN":1760},"Prolonged length of stay and discharge disposition to rehabilitation facilities following single-level posterior lumbar interbody fusion for acquired spondylolisthesis",{"VOID":1762},"33365174",{"VOID":1764},"10.25259\u002Fsni_707_2020",[91],"http:\u002F\u002Fsurgicalneurologyint.com\u002Fsurgicalint-articles\u002Fprolonged-length-of-stay-and-discharge-disposition-to-rehabilitation-facilities-following-single-level-posterior-lumbar-interbody-fusion-for-acquired-spondylolisthesis\u002F",[1768,1787,1804,1821,1838,1855,1874],{"id":1769,"sortIndex":23,"researcher":22,"roles":1770,"affiliations":1771,"properties":1780,"displayName":1784,"givenName":22,"familyName":22},"f455db44-5be9-4a9c-b1e9-1cff29d77637",[],[1772],{"id":1773,"sortIndex":23,"affiliation":1774,"properties":22},"71564346-9c27-41ce-97aa-7888514d26ce",{"id":1773,"createTime":22,"updateTime":22,"relativeEntities":1775,"slug":22,"properties":1776,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":1779,"statistic":22},[],{"title":1777},{"EN":1778},"Department of Neurological Surgery, Montefiore Medical Center, New York, United States.",[],{"orcid":1781,"title":1783,"openalex":1785},{"VOID":1782},"https:\u002F\u002Forcid.org\u002F0000-0001-8854-7155",{"EN":1784},"Joshua Benton",{"VOID":1786},"A5054591589",{"id":1788,"sortIndex":113,"researcher":22,"roles":1789,"affiliations":1790,"properties":1797,"displayName":1801,"givenName":22,"familyName":22},"3ba82421-a961-4397-bb76-2d875b7d8c71",[],[1791],{"id":1773,"sortIndex":23,"affiliation":1792,"properties":22},{"id":1773,"createTime":22,"updateTime":22,"relativeEntities":1793,"slug":22,"properties":1794,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":1796,"statistic":22},[],{"title":1795},{"EN":1778},[],{"orcid":1798,"title":1800,"openalex":1802},{"VOID":1799},"https:\u002F\u002Forcid.org\u002F0000-0002-5536-2514",{"EN":1801},"Rafael De la Garza Ramos",{"VOID":1803},"A5014224271",{"id":1805,"sortIndex":129,"researcher":22,"roles":1806,"affiliations":1807,"properties":1814,"displayName":1818,"givenName":22,"familyName":22},"2dc13b4e-cceb-45ba-8b68-6845438da02a",[],[1808],{"id":1773,"sortIndex":23,"affiliation":1809,"properties":22},{"id":1773,"createTime":22,"updateTime":22,"relativeEntities":1810,"slug":22,"properties":1811,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":1813,"statistic":22},[],{"title":1812},{"EN":1778},[],{"orcid":1815,"title":1817,"openalex":1819},{"VOID":1816},"https:\u002F\u002Forcid.org\u002F0000-0002-0920-8911",{"EN":1818},"Yaroslav Gelfand",{"VOID":1820},"A5010068058",{"id":1822,"sortIndex":1306,"researcher":22,"roles":1823,"affiliations":1824,"properties":1833,"displayName":1835,"givenName":22,"familyName":22},"8bf3b296-8684-4b91-a3e3-b4f344a9c574",[],[1825],{"id":1826,"sortIndex":23,"affiliation":1827,"properties":22},"ec682ff9-278e-4fd7-a0a0-498734501df8",{"id":1826,"createTime":22,"updateTime":22,"relativeEntities":1828,"slug":22,"properties":1829,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":1832,"statistic":22},[],{"title":1830},{"EN":1831},"Department of Orthopaedic Surgery, Montefiore Medical Center, New York, United States.",[],{"title":1834,"openalex":1836},{"EN":1835},"Jonathan Krystal",{"VOID":1837},"A5020303933",{"id":1839,"sortIndex":1326,"researcher":22,"roles":1840,"affiliations":1841,"properties":1848,"displayName":1852,"givenName":22,"familyName":22},"9deab3ca-7b31-4cb8-bd29-14b4f9ba0274",[],[1842],{"id":1773,"sortIndex":23,"affiliation":1843,"properties":22},{"id":1773,"createTime":22,"updateTime":22,"relativeEntities":1844,"slug":22,"properties":1845,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":1847,"statistic":22},[],{"title":1846},{"EN":1778},[],{"orcid":1849,"title":1851,"openalex":1853},{"VOID":1850},"https:\u002F\u002Forcid.org\u002F0000-0002-2456-5888",{"EN":1852},"Vijay Yanamadala",{"VOID":1854},"A5028068504",{"id":1856,"sortIndex":1346,"researcher":22,"roles":1857,"affiliations":1858,"properties":1867,"displayName":1871,"givenName":22,"familyName":22},"15951166-9106-449d-a9be-f8a6faec33eb",[],[1859],{"id":1860,"sortIndex":23,"affiliation":1861,"properties":22},"edfe5d6c-55e6-4990-8fa1-fdd11138bd63",{"id":1860,"createTime":22,"updateTime":22,"relativeEntities":1862,"slug":22,"properties":1863,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":1866,"statistic":22},[],{"title":1864},{"EN":1865},"Department of Neurosurgery, Montefiore Medical Center, New York, United States.",[],{"orcid":1868,"title":1870,"openalex":1872},{"VOID":1869},"https:\u002F\u002Forcid.org\u002F0000-0002-2593-2635",{"EN":1871},"Reza Yassari",{"VOID":1873},"A5076430359",{"id":1875,"sortIndex":1364,"researcher":22,"roles":1876,"affiliations":1877,"properties":1884,"displayName":1886,"givenName":22,"familyName":22},"fbfad5c1-1c92-4c75-b46c-17db2dc1ac77",[],[1878],{"id":1773,"sortIndex":23,"affiliation":1879,"properties":22},{"id":1773,"createTime":22,"updateTime":22,"relativeEntities":1880,"slug":22,"properties":1881,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":1883,"statistic":22},[],{"title":1882},{"EN":1778},[],{"title":1885,"openalex":1887},{"EN":1886},"Merritt D. Kinon",{"VOID":1888},"A5114168176",{"url":22,"publisher":1890,"properties":1919},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1891,"slug":10,"properties":1892,"entityType":20,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":23,"subjectFields":1896,"manageAffiliations":1905,"indexDatabases":1911,"url":64,"thumbnailPath":22,"statistic":22,"gsStatistic":22,"type":22,"analyzePriority":22},[],{"issn":1893,"title":1894,"country":1895},{"VOID":15},{"EN":17},{"VOID":13},[1897,1901],{"id":26,"createTime":22,"updateTime":22,"relativeEntities":1898,"label":1899,"description":1900,"parentId":22,"standard":22,"scholarHubFieldId":22},[],{"EN":29},{},{"id":32,"createTime":22,"updateTime":22,"relativeEntities":1902,"label":1903,"description":1904,"parentId":22,"standard":22,"scholarHubFieldId":22},[],{"EN":35},{},[1906],{"id":39,"createTime":22,"updateTime":22,"relativeEntities":1907,"slug":22,"properties":1908,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":1910,"statistic":22},[],{"title":1909},{"EN":43},[],[1912],{"id":47,"indexDatabase":1913,"url":58,"indexYears":59,"academicFieldIds":1918,"indexDatabaseRanking":63},{"id":49,"createTime":22,"updateTime":22,"relativeEntities":1914,"label":1915,"description":1916,"key":55,"publicationTags":1917,"standard":22},[],{"EN":52,"VI":52},{"EN":52,"VI":54},[57],[61,62],{"pages":1920,"volume":1922},{"VOID":1921},"411",{"VOID":1923},"11",11,{"total":1924,"publishYear":22,"statisticByYear":1926},{"2021":1306,"2022":129,"2023":1326,"2024":129},[],[1929,1933,1937,1941,1945,1949,1953,1957,1961],{"id":22,"text":1930,"url":22,"identifiers":1931},"Epstein, 2011, Surgeon choices, and the choice of surgeons, affect total hospital charges for single-level anterior cervical surgery, Spine (Phila Pa 1976), 36, 905, 10.1097\u002FBRS.0b013e3181e6c4d8",{"doi":1932},"10.1097\u002FBRS.0b013e3181e6c4d8",{"id":22,"text":1934,"url":22,"identifiers":1935},"Goz, 2014, Comparison of complications, costs, and length of stay of three different lumbar interbody fusion techniques: An analysis of the nationwide inpatient sample database, Spine J, 14, 2019, 10.1016\u002Fj.spinee.2013.11.050",{"doi":1936},"10.1016\u002Fj.spinee.2013.11.050",{"id":22,"text":1938,"url":22,"identifiers":1939},"Guzman, 2014, Outcomes and complications of diabetes mellitus on patients undergoing degenerative lumbar spine surgery, Spine (Phila Pa 1976), 39, 1596, 10.1097\u002FBRS.0000000000000482",{"doi":1940},"10.1097\u002FBRS.0000000000000482",{"id":22,"text":1942,"url":22,"identifiers":1943},"Malik, 2019, Discharge to inpatient care facility after anterior lumbar interbody fusion: Incidence, predictors, and postdischarge outcomes, World Neurosurg, 122, e584, 10.1016\u002Fj.wneu.2018.10.108",{"doi":1944},"10.1016\u002Fj.wneu.2018.10.108",{"id":22,"text":1946,"url":22,"identifiers":1947},"Passias, 2018, Predictors of adverse discharge disposition in adult spinal deformity and associated costs, Spine J, 18, 1845, 10.1016\u002Fj.spinee.2018.03.022",{"doi":1948},"10.1016\u002Fj.spinee.2018.03.022",{"id":22,"text":1950,"url":22,"identifiers":1951},"Purvis, 2017, Effect of liberal blood transfusion on clinical outcomes and cost in spine surgery patients, Spine J, 17, 1255, 10.1016\u002Fj.spinee.2017.04.028",{"doi":1952},"10.1016\u002Fj.spinee.2017.04.028",{"id":22,"text":1954,"url":22,"identifiers":1955},"Seicean, 2013, Preoperative anemia and perioperative outcomes in patients who undergo elective spine surgery, Spine (Phila Pa 1976), 38, 1331, 10.1097\u002FBRS.0b013e3182912c6b",{"doi":1956},"10.1097\u002FBRS.0b013e3182912c6b",{"id":22,"text":1958,"url":22,"identifiers":1959},"Vincent, 2011, Diabetic neuropathy: Cellular mechanisms as therapeutic targets, Nat Rev Neurol, 7, 573, 10.1038\u002Fnrneurol.2011.137",{"doi":1960},"10.1038\u002Fnrneurol.2011.137",{"id":22,"text":1962,"url":22,"identifiers":1963},"Weaver, 2019, The modified 5-item frailty index: A concise and useful tool for assessing the impact of frailty on postoperative morbidity following elective posterior lumbar fusions, World Neurosurg, 124, e626, 10.1016\u002Fj.wneu.2018.12.168",{"doi":1964},"10.1016\u002Fj.wneu.2018.12.168",{"id":1966,"createTime":1967,"updateTime":1967,"relativeEntities":1968,"slug":1969,"properties":1970,"entityType":87,"verifyStatus":88,"verifyTime":1985,"verifyNote":89,"languages":1986,"translateLanguages":22,"viewCount":23,"primaryUrl":1987,"fullTextUrl":22,"authors":1988,"publicationType":147,"publisherRelationship":2060,"citationCount":1306,"citationInfo":2094,"publishDate":22,"publishYear":22,"citationAnalyzeStatus":21,"lastCitationAnalyze":22,"indexDatabases":2096,"openAccess":22,"references":2097,"isForceReanalyzing":1057},"14ed8627-3c18-4bf2-b782-967a798265db","2024-12-06T02:10:51.840+00:00",[],"Osimertinib-induced-rapid-regression-of-large-metastatic-tumor-to-the-pituitary-in-a-patient-with-lung-adenocarcinoma",{"mag":1971,"pmc":1973,"openalex":1975,"abstract":1977,"title":1979,"pm":1981,"doi":1983},{"VOID":1972},"3120094360",{"VOID":1974},"7827509",{"VOID":1976},"W3120094360",{"EN":1978},"\u003Cjats:sec id=\"st1\">\n\u003Cjats:title>Background: \u003C\u002Fjats:title>\n\u003Cjats:p>Metastatic nonsmall cell lung cancer (NSCLC) to the pituitary (NSCLC-PitM) is rare and often presents with visual field deficits. Surgical resection for the decompression of the optic apparatus has been the treatment of choice in such cases. Osimertinib is a third-generation tyrosine kinase inhibitor (TKI) approved for the treatment of patients with NSCLC with an epithelial growth factor receptor (EGFR) mutation though its role in the treatment of NSCLC-PitM that remains unclear. We present a case of NSCLC-PitM with optic chiasm compression and visual deficits that were successfully treated with osimertinib alone without surgical intervention.\u003C\u002Fjats:p>\n\u003C\u002Fjats:sec>\n\u003Cjats:sec id=\"st2\">\n\u003Cjats:title>Case Description: \u003C\u002Fjats:title>\n\u003Cjats:p>A 43-year-old male presented with pleuritic chest pain, fatigue, and visual deficits found to have NSCLC and a sellar mass with suprasellar extension and optic chiasm compression. Visual field testing demonstrated associated visual field deficits. Molecular testing was positive for EGFR exon 19 deletion. The patient was started on osimertinib with complete resolution of pituitary lesion and visual deficits at 4 weeks.\u003C\u002Fjats:p>\n\u003C\u002Fjats:sec>\n\u003Cjats:sec id=\"st3\">\n\u003Cjats:title>Conclusion: \u003C\u002Fjats:title>\n\u003Cjats:p>Osimertinib is a third-generation EGFR-TKI that has demonstrated promising results among patients with metastatic EGFR-mutated NSCLC. While surgery is the mainstay of treatment in patients with a sellar mass, optic compression, and visual deficits, those with EGFR-mutated NSCLC-PitM may benefit from early initiation of such systemic therapies, rather than surgical intervention, with good ophthalmologic results.\u003C\u002Fjats:p>\n\u003C\u002Fjats:sec>",{"EN":1980},"Osimertinib-induced rapid regression of large metastatic tumor to the pituitary in a patient with lung adenocarcinoma",{"VOID":1982},"33500828",{"VOID":1984},"10.25259\u002Fsni_629_2020","2024-12-06T02:10:51.839+00:00",[91],"http:\u002F\u002Fsurgicalneurologyint.com\u002Fsurgicalint-articles\u002Fosimertinib-induced-rapid-regression-of-large-metastatic-tumor-to-the-pituitary-in-a-patient-with-lung-adenocarcinoma\u002F",[1989,2008,2041],{"id":1990,"sortIndex":23,"researcher":22,"roles":1991,"affiliations":1992,"properties":2001,"displayName":2005,"givenName":22,"familyName":22},"e02b9504-95cf-4dcd-8b83-9f2ae4296b76",[],[1993],{"id":1994,"sortIndex":23,"affiliation":1995,"properties":22},"6beccd91-4e67-45e9-867a-acee4fae63e9",{"id":1994,"createTime":22,"updateTime":22,"relativeEntities":1996,"slug":22,"properties":1997,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":2000,"statistic":22},[],{"title":1998},{"EN":1999},"Department of Neurosurgery, Rush University Medical Center, Chicago, Departments of 2 Ophthalmology,",[],{"orcid":2002,"title":2004,"openalex":2006},{"VOID":2003},"https:\u002F\u002Forcid.org\u002F0000-0001-6896-0946",{"EN":2005},"Andrew K. Wong",{"VOID":2007},"A5013052106",{"id":2009,"sortIndex":113,"researcher":22,"roles":2010,"affiliations":2011,"properties":2036,"displayName":2038,"givenName":22,"familyName":22},"1aa811ec-8f8a-48f0-8e03-455c063a4631",[],[2012,2020,2028],{"id":2013,"sortIndex":23,"affiliation":2014,"properties":22},"2e93ee6e-4426-432e-97f3-74ba542fcc9c",{"id":2013,"createTime":22,"updateTime":22,"relativeEntities":2015,"slug":22,"properties":2016,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":2019,"statistic":22},[],{"title":2017},{"EN":2018},"Clinical Professor of Neurological Surgery, School of Medicine, State U. of NY at Stony Brook.",[],{"id":2021,"sortIndex":113,"affiliation":2022,"properties":22},"803c0005-c7f3-4058-878b-9069aaa172d2",{"id":2021,"createTime":22,"updateTime":22,"relativeEntities":2023,"slug":22,"properties":2024,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":2027,"statistic":22},[],{"title":2025},{"EN":2026},"Department of Ophthalmology, North Shore University Health System, Evanston, Illinois, United States.",[],{"id":2029,"sortIndex":129,"affiliation":2030,"properties":22},"cb9eeebb-7b00-41fb-a18a-4cd646501f05",{"id":2029,"createTime":22,"updateTime":22,"relativeEntities":2031,"slug":22,"properties":2032,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":2035,"statistic":22},[],{"title":2033},{"VI":2034},"Kanazawa University, Ishikawa, Japan",[],{"title":2037,"openalex":2039},{"EN":2038},"Troy W. Close",{"VOID":2040},"A5052736273",{"id":2042,"sortIndex":129,"researcher":22,"roles":2043,"affiliations":2044,"properties":2053,"displayName":2057,"givenName":22,"familyName":22},"f5a0cb96-a318-4bf6-b583-072ba9c51bdc",[],[2045],{"id":2046,"sortIndex":23,"affiliation":2047,"properties":22},"548a10ec-fe81-4d89-af48-17c14ba2cde9",{"id":2046,"createTime":22,"updateTime":22,"relativeEntities":2048,"slug":22,"properties":2049,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":2052,"statistic":22},[],{"title":2050},{"EN":2051},"Department of Neurosurgery, North Shore University Health System, Evanston, Illinois, United States.",[],{"orcid":2054,"title":2056,"openalex":2058},{"VOID":2055},"https:\u002F\u002Forcid.org\u002F0000-0002-0571-3590",{"EN":2057},"Ricky H. Wong",{"VOID":2059},"A5070719782",{"url":22,"publisher":2061,"properties":2090},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":2062,"slug":10,"properties":2063,"entityType":20,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":23,"subjectFields":2067,"manageAffiliations":2076,"indexDatabases":2082,"url":64,"thumbnailPath":22,"statistic":22,"gsStatistic":22,"type":22,"analyzePriority":22},[],{"issn":2064,"title":2065,"country":2066},{"VOID":15},{"EN":17},{"VOID":13},[2068,2072],{"id":26,"createTime":22,"updateTime":22,"relativeEntities":2069,"label":2070,"description":2071,"parentId":22,"standard":22,"scholarHubFieldId":22},[],{"EN":29},{},{"id":32,"createTime":22,"updateTime":22,"relativeEntities":2073,"label":2074,"description":2075,"parentId":22,"standard":22,"scholarHubFieldId":22},[],{"EN":35},{},[2077],{"id":39,"createTime":22,"updateTime":22,"relativeEntities":2078,"slug":22,"properties":2079,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":2081,"statistic":22},[],{"title":2080},{"EN":43},[],[2083],{"id":47,"indexDatabase":2084,"url":58,"indexYears":59,"academicFieldIds":2089,"indexDatabaseRanking":63},{"id":49,"createTime":22,"updateTime":22,"relativeEntities":2085,"label":2086,"description":2087,"key":55,"publicationTags":2088,"standard":22},[],{"EN":52,"VI":52},{"EN":52,"VI":54},[57],[61,62],{"pages":2091,"volume":2093},{"VOID":2092},"13",{"VOID":1429},{"total":1306,"publishYear":22,"statisticByYear":2095},{"2021":113,"2022":113,"2023":113},[],[2098,2101,2105,2109,2113,2117,2121,2125,2128,2132,2136],{"id":22,"text":2099,"url":22,"identifiers":2100},"Adashek, 2018, EGFR T790M-positive lung adenocarcinoma metastases to the pituitary gland causing adrenal insufficiency: A case report, Case Rep Oncol Med, 2018, 2349021",{},{"id":22,"text":2102,"url":22,"identifiers":2103},"Ayeni, 2015, Emerging agents and new mutations in EGFR-mutant lung cancer, Clin Cancer Res, 21, 3818, 10.1158\u002F1078-0432.CCR-15-1211",{"doi":2104},"10.1158\u002F1078-0432.CCR-15-1211",{"id":22,"text":2106,"url":22,"identifiers":2107},"Ballard, 2016, Preclinical comparison of osimertinib with other EGFRTKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity, Clin Cancer Res, 22, 5130, 10.1158\u002F1078-0432.CCR-16-0399",{"doi":2108},"10.1158\u002F1078-0432.CCR-16-0399",{"id":22,"text":2110,"url":22,"identifiers":2111},"Fan, 2019, Complete resolution of sellar metastasis in a patient With NSCLC treated with osimertinib, J Endocr Soc, 3, 1887, 10.1210\u002Fjs.2019-00217",{"doi":2112},"10.1210\u002Fjs.2019-00217",{"id":22,"text":2114,"url":22,"identifiers":2115},"Javanbakht, 2018, Pituitary metastasis: A rare condition, Endocr Connect, 7, 1049, 10.1530\u002FEC-18-0338",{"doi":2116},"10.1530\u002FEC-18-0338",{"id":22,"text":2118,"url":22,"identifiers":2119},"Megyesi, 2019, P14.111 Successful treatment of extensive metastatic disease with successive use of two different EGF receptor antagonists: Case report and review of the literature, Neuro Oncol, 21, iii94, 10.1093\u002Fneuonc\u002Fnoz126.346",{"doi":2120},"10.1093\u002Fneuonc\u002Fnoz126.346",{"id":22,"text":2122,"url":22,"identifiers":2123},"Mok, 2017, Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer, New Engl J Med, 376, 629, 10.1056\u002FNEJMoa1612674",{"doi":2124},"10.1056\u002FNEJMoa1612674",{"id":22,"text":2126,"url":22,"identifiers":2127},"Okauchi, 2018, Paradoxical response to osimertinib therapy in a patient with T790M-mutated lung adenocarcinoma, Mol Clin Oncol, 8, 175",{},{"id":22,"text":2129,"url":22,"identifiers":2130},"Rahmathulla, 2012, The molecular biology of brain metastasis, J Oncol, 2012, 723541, 10.1155\u002F2012\u002F723541",{"doi":2131},"10.1155\u002F2012\u002F723541",{"id":22,"text":2133,"url":22,"identifiers":2134},"Shan, 2019, CMET-10, Intracranial solitary pituitary metastasis: The implications from five cases, Neuro Oncol, 21, vi53, 10.1093\u002Fneuonc\u002Fnoz175.211",{"doi":2135},"10.1093\u002Fneuonc\u002Fnoz175.211",{"id":22,"text":2137,"url":22,"identifiers":2138},"Soria, 2018, Osimertinib in untreated EGFR-mutated advanced nonsmall-cell lung cancer, N Engl J Med, 378, 113, 10.1056\u002FNEJMoa1713137",{"doi":2139},"10.1056\u002FNEJMoa1713137",{"id":2141,"createTime":2142,"updateTime":2142,"relativeEntities":2143,"slug":2144,"properties":2145,"entityType":87,"verifyStatus":88,"verifyTime":2160,"verifyNote":89,"languages":2161,"translateLanguages":22,"viewCount":23,"primaryUrl":2162,"fullTextUrl":22,"authors":2163,"publicationType":147,"publisherRelationship":2240,"citationCount":1924,"citationInfo":2275,"publishDate":22,"publishYear":22,"citationAnalyzeStatus":21,"lastCitationAnalyze":22,"indexDatabases":2277,"openAccess":22,"references":2278,"isForceReanalyzing":1057},"9f2c91c1-6f2b-430c-8406-be6e2f0f4bc5","2024-10-14T11:39:26.496+00:00",[],"A-case-of-cardiac-tamponade-during-the-treatment-of-simultaneous-cardio-cerebral-infarction-associated-with-atrial-fibrillation-Case-report",{"mag":2146,"pmc":2148,"openalex":2150,"abstract":2152,"title":2154,"pm":2156,"doi":2158},{"VOID":2147},"2991835304",{"VOID":2149},"6911677",{"VOID":2151},"W2991835304",{"EN":2153},"\u003Cjats:sec id=\"st1\">\n\u003Cjats:title>Background:\u003C\u002Fjats:title>\n\u003Cjats:p>Simultaneous cerebral and myocardial infarction is called cardio-cerebral infarction (CCI). It is a rare condition, and its management strategy has yet to be determined. We report a case of cardiac tamponade during the treatment of CCI associated with atrial fibrillation.\u003C\u002Fjats:p>\n\u003C\u002Fjats:sec>\n\u003Cjats:sec id=\"st2\">\n\u003Cjats:title>Case Description:\u003C\u002Fjats:title>\n\u003Cjats:p>A 72-year-old man presented with loss of consciousness after chest discomfort. He had taken rivaroxaban for paroxysmal atrial fibrillation. Twelve-lead electrocardiography showed ST elevation at II, III, and aVF. His National Institutes of Health Stroke Scale was 29. We diagnosed him with synchronous cardioembolic stroke and acute myocardial infarction due to atrial fibrillation. The coronary angiography revealed distal occlusion in the posterior descending branch of the right coronary artery, and overall myocardial perfusion seemed sufficient. The diffusion-weighted image showed hyperintense lesions at the cerebellum, and magnetic resonance angiography did not reveal the flow of the basilar artery. The patient’s NIH score improved immediately, so we did not perform intravenous tissue plasminogen activator (IV-tPA) administration nor endovascular treatment. Heparin administration was started. After 38 h from the onset, he suffered from hydrocephalus, and cerebral ventricular drainage was performed. Subsequently, circulatory dynamics worsened, and he was diagnosed with cardiac tamponade. Emergency pericardiotomy was performed, and he has been taking intensive care.\u003C\u002Fjats:p>\n\u003C\u002Fjats:sec>\n\u003Cjats:sec id=\"st3\">\n\u003Cjats:title>Conclusion:\u003C\u002Fjats:title>\n\u003Cjats:p>Some cases with CCI treated with IV-tPA and endovascular intervention were reported, but the treatment strategy should be still discussed multidisciplinary. Especially, the administration of antithrombotic drugs for CCI should be carefully performed because fatal hemorrhage such as cardiac tamponade can occur.\u003C\u002Fjats:p>\n\u003C\u002Fjats:sec>",{"EN":2155},"A case of cardiac tamponade during the treatment of simultaneous cardio-cerebral infarction associated with atrial fibrillation – Case report",{"VOID":2157},"31893142",{"VOID":2159},"10.25259\u002Fsni_504_2019","2024-10-14T11:39:26.495+00:00",[91],"http:\u002F\u002Fsurgicalneurologyint.com\u002Fsurgicalint-articles\u002Fa-case-of-cardiac-tamponade-during-the-treatment-of-simultaneous-cardio-cerebral-infarction-associated-with-atrial-fibrillation-case-report\u002F",[2164,2207],{"id":2165,"sortIndex":23,"researcher":22,"roles":2166,"affiliations":2167,"properties":2200,"displayName":2204,"givenName":22,"familyName":22},"f33565e3-0c80-4d54-8013-6a061fd392cb",[],[2168,2176,2184,2192],{"id":2169,"sortIndex":23,"affiliation":2170,"properties":22},"15b73665-0bc3-415c-83ba-29b347d20e02",{"id":2169,"createTime":22,"updateTime":22,"relativeEntities":2171,"slug":22,"properties":2172,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":2175,"statistic":22},[],{"title":2173},{"EN":2174},"Katsuki Clinic, 21-3, Koganedai, Higashi-ward, Niigata, Japan.",[],{"id":2177,"sortIndex":113,"affiliation":2178,"properties":22},"14274b57-1367-4d90-8103-010ad2b571e0",{"id":2177,"createTime":22,"updateTime":22,"relativeEntities":2179,"slug":22,"properties":2180,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":2183,"statistic":22},[],{"title":2181},{"EN":2182},"Katsuki Clinic, 21-3, Koganedai, Higashi-ward, Niigata-city, Niigata 950-0028, Japan.",[],{"id":2185,"sortIndex":129,"affiliation":2186,"properties":22},"12004e32-1242-4f42-8470-fafd9ecd2b48",{"id":2185,"createTime":22,"updateTime":22,"relativeEntities":2187,"slug":22,"properties":2188,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":2191,"statistic":22},[],{"title":2189},{"EN":2190},"NYU Winthrop Hospital, Mineola, NY, USA.",[],{"id":2193,"sortIndex":1306,"affiliation":2194,"properties":22},"fcc1f104-8f8d-4822-98b8-7cdd9dbd842a",{"id":2193,"createTime":22,"updateTime":22,"relativeEntities":2195,"slug":22,"properties":2196,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":2199,"statistic":22},[],{"title":2197},{"EN":2198},"Shinsui University, Matsomoto, Japan",[],{"orcid":2201,"title":2203,"openalex":2205},{"VOID":2202},"https:\u002F\u002Forcid.org\u002F0000-0002-0192-5430",{"EN":2204},"Masahito Katsuki",{"VOID":2206},"A5015125363",{"id":2208,"sortIndex":113,"researcher":22,"roles":2209,"affiliations":2210,"properties":2235,"displayName":2237,"givenName":22,"familyName":22},"4bb922de-aa56-4b6e-b9ca-7ea79b5858c5",[],[2211,2217,2223,2229],{"id":2169,"sortIndex":23,"affiliation":2212,"properties":22},{"id":2169,"createTime":22,"updateTime":22,"relativeEntities":2213,"slug":22,"properties":2214,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":2216,"statistic":22},[],{"title":2215},{"EN":2174},[],{"id":2177,"sortIndex":113,"affiliation":2218,"properties":22},{"id":2177,"createTime":22,"updateTime":22,"relativeEntities":2219,"slug":22,"properties":2220,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":2222,"statistic":22},[],{"title":2221},{"EN":2182},[],{"id":2185,"sortIndex":129,"affiliation":2224,"properties":22},{"id":2185,"createTime":22,"updateTime":22,"relativeEntities":2225,"slug":22,"properties":2226,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":2228,"statistic":22},[],{"title":2227},{"EN":2190},[],{"id":2193,"sortIndex":1306,"affiliation":2230,"properties":22},{"id":2193,"createTime":22,"updateTime":22,"relativeEntities":2231,"slug":22,"properties":2232,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":2234,"statistic":22},[],{"title":2233},{"EN":2198},[],{"title":2236,"openalex":2238},{"EN":2237},"Shigemi Katsuki",{"VOID":2239},"A5066080199",{"url":22,"publisher":2241,"properties":2270},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":2242,"slug":10,"properties":2243,"entityType":20,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":23,"subjectFields":2247,"manageAffiliations":2256,"indexDatabases":2262,"url":64,"thumbnailPath":22,"statistic":22,"gsStatistic":22,"type":22,"analyzePriority":22},[],{"issn":2244,"title":2245,"country":2246},{"VOID":15},{"EN":17},{"VOID":13},[2248,2252],{"id":26,"createTime":22,"updateTime":22,"relativeEntities":2249,"label":2250,"description":2251,"parentId":22,"standard":22,"scholarHubFieldId":22},[],{"EN":29},{},{"id":32,"createTime":22,"updateTime":22,"relativeEntities":2253,"label":2254,"description":2255,"parentId":22,"standard":22,"scholarHubFieldId":22},[],{"EN":35},{},[2257],{"id":39,"createTime":22,"updateTime":22,"relativeEntities":2258,"slug":22,"properties":2259,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":2261,"statistic":22},[],{"title":2260},{"EN":43},[],[2263],{"id":47,"indexDatabase":2264,"url":58,"indexYears":59,"academicFieldIds":2269,"indexDatabaseRanking":63},{"id":49,"createTime":22,"updateTime":22,"relativeEntities":2265,"label":2266,"description":2267,"key":55,"publicationTags":2268,"standard":22},[],{"EN":52,"VI":52},{"EN":52,"VI":54},[57],[61,62],{"pages":2271,"volume":2273},{"VOID":2272},"241",{"VOID":2274},"10",{"total":1924,"publishYear":22,"statisticByYear":2276},{"2015":129,"2021":1326,"2022":129,"2023":1306},[],[2279,2283,2286,2290,2294,2298,2302,2306,2310,2314,2318,2322,2326,2330,2333],{"id":22,"text":2280,"url":22,"identifiers":2281},"Abe, 2019, Simultaneous cardio-cerebral embolization associated with atrial fibrillation: A case report, BMC Neurol, 19, 152, 10.1186\u002Fs12883-019-1388-1",{"doi":2282},"10.1186\u002Fs12883-019-1388-1",{"id":22,"text":2284,"url":22,"identifiers":2285},"Bersano, 2014, Tako-tsubo syndrome as a consequence and cause of stroke, Funct Neurol, 29, 135",{},{"id":22,"text":2287,"url":22,"identifiers":2288},"Chin, 1977, Myocardial infarction coincident with cerebrovascular accidents in the elderly, Age Ageing, 6, 29, 10.1093\u002Fageing\u002F6.1.29",{"doi":2289},"10.1093\u002Fageing\u002F6.1.29",{"id":22,"text":2291,"url":22,"identifiers":2292},"Chlapoutakis, 2010, Acute myocardial infarction and transient ischemic attack in a patient with lone atrial fibrillation and normal coronary arteries, Int J Cardiol, 139, e1, 10.1016\u002Fj.ijcard.2008.06.085",{"doi":2293},"10.1016\u002Fj.ijcard.2008.06.085",{"id":22,"text":2295,"url":22,"identifiers":2296},"Gianstefani, 2014, Incidence and predictors of early left ventricular thrombus after ST-elevation myocardial infarction in the contemporary era of primary percutaneous coronary intervention, Am J Cardiol, 113, 1111, 10.1016\u002Fj.amjcard.2013.12.015",{"doi":2297},"10.1016\u002Fj.amjcard.2013.12.015",{"id":22,"text":2299,"url":22,"identifiers":2300},"González-Pacheco, 2014, Reperfusion strategy for simultaneous ST-segment elevation myocardial infarction and acute ischemic stroke within a time window, Am J Emerg Med, 32, 1157.e1, 10.1016\u002Fj.ajem.2014.02.047",{"doi":2301},"10.1016\u002Fj.ajem.2014.02.047",{"id":22,"text":2303,"url":22,"identifiers":2304},"Gungoren, 2019, Optimal treatment modality for coexisting acute myocardial infarction and ischemic stroke, Am J Emerg Med, 37, 795.e1, 10.1016\u002Fj.ajem.2018.12.060",{"doi":2305},"10.1016\u002Fj.ajem.2018.12.060",{"id":22,"text":2307,"url":22,"identifiers":2308},"Kijpaisalratana, 2017, Hyperacute simultaneous cardiocerebral infarction: Rescuing the brain or the heart first?, Front Neurol, 8, 664, 10.3389\u002Ffneur.2017.00664",{"doi":2309},"10.3389\u002Ffneur.2017.00664",{"id":22,"text":2311,"url":22,"identifiers":2312},"Maciel, 2015, Acute stroke with concomitant acute myocardial infarction: Will you thrombolyse?, J Stroke, 17, 84, 10.5853\u002Fjos.2015.17.1.84",{"doi":2313},"10.5853\u002Fjos.2015.17.1.84",{"id":22,"text":2315,"url":22,"identifiers":2316},"Nagasawa, 2014, Case of cardiac tamponade during the treatment of acute cerebral infarction, Rinsho Shinkeigaku, 54, 218, 10.5692\u002Fclinicalneurol.54.218",{"doi":2317},"10.5692\u002Fclinicalneurol.54.218",{"id":22,"text":2319,"url":22,"identifiers":2320},"Obaid, 2019, Simultaneous acute anterior ST-elevation myocardial infarction and acute ischemic stroke of left middle cerebral artery: A case report, Am J Case Rep, 20, 776, 10.12659\u002FAJCR.916114",{"doi":2321},"10.12659\u002FAJCR.916114",{"id":22,"text":2323,"url":22,"identifiers":2324},"Omar, 2010, Concomitant acute right ventricular infarction and ischemic cerebrovascular stroke; possible explanations, Int Arch Med, 3, 25, 10.1186\u002F1755-7682-3-25",{"doi":2325},"10.1186\u002F1755-7682-3-25",{"id":22,"text":2327,"url":22,"identifiers":2328},"Patel, 2011, Rivaroxaban versus warfarin in nonvalvular atrial fibrillation, N Engl J Med, 365, 883, 10.1056\u002FNEJMoa1009638",{"doi":2329},"10.1056\u002FNEJMoa1009638",{"id":22,"text":2331,"url":22,"identifiers":2332},"Powers, 2019, Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: A guideline for healthcare professionals from the American Heart Association\u002FAmerican Stroke Association, Stroke, 49, e46",{},{"id":22,"text":2334,"url":22,"identifiers":2335},"Yeo, 2017, Synchronous cardiocerebral infarction in the era of endovascular therapy: Which to treat first?, J Thromb Thrombolysis, 44, 104, 10.1007\u002Fs11239-017-1484-2",{"doi":2336},"10.1007\u002Fs11239-017-1484-2",{"id":2338,"createTime":2339,"updateTime":2339,"relativeEntities":2340,"slug":2341,"properties":2342,"entityType":87,"verifyStatus":88,"verifyTime":2357,"verifyNote":89,"languages":2358,"translateLanguages":22,"viewCount":23,"primaryUrl":2359,"fullTextUrl":22,"authors":2360,"publicationType":147,"publisherRelationship":2438,"citationCount":1306,"citationInfo":2472,"publishDate":22,"publishYear":22,"citationAnalyzeStatus":21,"lastCitationAnalyze":22,"indexDatabases":2474,"openAccess":22,"references":2475,"isForceReanalyzing":1057},"25665fab-be66-4f98-94a2-67f05fef7a46","2024-10-08T07:55:50.226+00:00",[],"Cerebral-venous-thrombosis-of-the-sphenoparietal-sinus-A-case-report",{"mag":2343,"pmc":2345,"openalex":2347,"abstract":2349,"title":2351,"pm":2353,"doi":2355},{"VOID":2344},"3165840426",{"VOID":2346},"8168662",{"VOID":2348},"W3165840426",{"EN":2350},"\u003Cjats:sec id=\"st1\">\n\u003Cjats:title>Background: \u003C\u002Fjats:title>\n\u003Cjats:p>Cerebral venous thrombosis (CVT) is a rare cause of stroke that preferentially affects reproductive aged females and patients with hereditary or acquired thrombotic risk factors. The superior sagittal sinus and transverse sinus are the two most common sites for thrombus formation.\u003C\u002Fjats:p>\n\u003C\u002Fjats:sec>\n\u003Cjats:sec id=\"st2\">\n\u003Cjats:title>Case Description: \u003C\u002Fjats:title>\n\u003Cjats:p>We report a case of CVT arising in a very rare location, the sphenoparietal sinus. A 32-year-old woman with a history of factor V Leiden mutation and multiple prior episodes of venous thromboembolism presented with a new-onset seizure, headache, and emesis. CT angiography ultimately revealed thrombosis of the left sphenoparietal sinus. The patient received anticoagulation with apixaban with resolution of symptoms and without complications.\u003C\u002Fjats:p>\n\u003C\u002Fjats:sec>\n\u003Cjats:sec id=\"st3\">\n\u003Cjats:title>Conclusion: \u003C\u002Fjats:title>\n\u003Cjats:p>This case serves as an uncommon example of sphenoparietal sinus thrombosis managed with novel oral anticoagulant treatment.\u003C\u002Fjats:p>\n\u003C\u002Fjats:sec>",{"EN":2352},"Cerebral venous thrombosis of the sphenoparietal sinus: A case report",{"VOID":2354},"34084624",{"VOID":2356},"10.25259\u002Fsni_126_2021","2024-10-08T07:55:50.225+00:00",[91],"http:\u002F\u002Fsurgicalneurologyint.com\u002Fsurgicalint-articles\u002Fcerebral-venous-thrombosis-of-the-sphenoparietal-sinus-a-case-report-2",[2361,2383,2402,2419],{"id":2362,"sortIndex":23,"researcher":22,"roles":2363,"affiliations":2364,"properties":2376,"displayName":2380,"givenName":22,"familyName":22},"705af94b-9ed5-4aff-aed2-4b6c3e5f7396",[],[2365],{"id":2366,"sortIndex":23,"affiliation":2367,"properties":2373},"7ba7e6ea-089a-41ae-b306-16e2594bf364",{"id":2366,"createTime":22,"updateTime":22,"relativeEntities":2368,"slug":22,"properties":2369,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":2372,"statistic":22},[],{"title":2370},{"VI":2371},"Department of Neurosurgery, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA",[],{"title":2374},{"EN":2375},"Department of Neurosurgery, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States.",{"orcid":2377,"title":2379,"openalex":2381},{"VOID":2378},"https:\u002F\u002Forcid.org\u002F0000-0001-7883-5612",{"EN":2380},"Camille K. Milton",{"VOID":2382},"A5081274133",{"id":2384,"sortIndex":113,"researcher":22,"roles":2385,"affiliations":2386,"properties":2395,"displayName":2399,"givenName":22,"familyName":22},"93eded83-36e3-4211-9e60-2cac95e78321",[],[2387],{"id":2388,"sortIndex":23,"affiliation":2389,"properties":22},"ab3fde59-809e-463a-9254-0a2aa707a40a",{"id":2388,"createTime":22,"updateTime":22,"relativeEntities":2390,"slug":22,"properties":2391,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":2394,"statistic":22},[],{"title":2392},{"EN":2393},"Department of Neurology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States.",[],{"orcid":2396,"title":2398,"openalex":2400},{"VOID":2397},"https:\u002F\u002Forcid.org\u002F0000-0003-3276-9685",{"EN":2399},"David Gordon",{"VOID":2401},"A5040961140",{"id":2403,"sortIndex":129,"researcher":22,"roles":2404,"affiliations":2405,"properties":2414,"displayName":2416,"givenName":22,"familyName":22},"ee004ac0-e698-4bb8-a781-1a88821638c8",[],[2406],{"id":2366,"sortIndex":23,"affiliation":2407,"properties":2412},{"id":2366,"createTime":22,"updateTime":22,"relativeEntities":2408,"slug":22,"properties":2409,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":2411,"statistic":22},[],{"title":2410},{"VI":2371},[],{"title":2413},{"EN":2375},{"title":2415,"openalex":2417},{"EN":2416},"Chad A. Glenn",{"VOID":2418},"A5017709824",{"id":2420,"sortIndex":1306,"researcher":22,"roles":2421,"affiliations":2422,"properties":2431,"displayName":2435,"givenName":22,"familyName":22},"58f385c8-de0d-4854-9f7f-1cb5768b66fb",[],[2423],{"id":2366,"sortIndex":23,"affiliation":2424,"properties":2429},{"id":2366,"createTime":22,"updateTime":22,"relativeEntities":2425,"slug":22,"properties":2426,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":2428,"statistic":22},[],{"title":2427},{"VI":2371},[],{"title":2430},{"EN":2375},{"orcid":2432,"title":2434,"openalex":2436},{"VOID":2433},"https:\u002F\u002Forcid.org\u002F0000-0002-7878-4461",{"EN":2435},"Andrew K. Conner",{"VOID":2437},"A5081159037",{"url":22,"publisher":2439,"properties":2468},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":2440,"slug":10,"properties":2441,"entityType":20,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":23,"subjectFields":2445,"manageAffiliations":2454,"indexDatabases":2460,"url":64,"thumbnailPath":22,"statistic":22,"gsStatistic":22,"type":22,"analyzePriority":22},[],{"issn":2442,"title":2443,"country":2444},{"VOID":15},{"EN":17},{"VOID":13},[2446,2450],{"id":26,"createTime":22,"updateTime":22,"relativeEntities":2447,"label":2448,"description":2449,"parentId":22,"standard":22,"scholarHubFieldId":22},[],{"EN":29},{},{"id":32,"createTime":22,"updateTime":22,"relativeEntities":2451,"label":2452,"description":2453,"parentId":22,"standard":22,"scholarHubFieldId":22},[],{"EN":35},{},[2455],{"id":39,"createTime":22,"updateTime":22,"relativeEntities":2456,"slug":22,"properties":2457,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":2459,"statistic":22},[],{"title":2458},{"EN":43},[],[2461],{"id":47,"indexDatabase":2462,"url":58,"indexYears":59,"academicFieldIds":2467,"indexDatabaseRanking":63},{"id":49,"createTime":22,"updateTime":22,"relativeEntities":2463,"label":2464,"description":2465,"key":55,"publicationTags":2466,"standard":22},[],{"EN":52,"VI":52},{"EN":52,"VI":54},[57],[61,62],{"pages":2469,"volume":2471},{"VOID":2470},"197",{"VOID":1429},{"total":1306,"publishYear":22,"statisticByYear":2473},{"2021":113,"2023":129},[],[2476,2479,2483,2487,2490,2493,2497,2501,2505,2509,2513,2517,2521,2524,2528,2532,2536,2540,2543],{"id":22,"text":2477,"url":22,"identifiers":2478},"2019, A Clinical Trial Comparing Efficacy and Safety of Dabigatran Etexilate with Warfarin in Patients with Cerebral Venous and Dural Sinus;",{},{"id":22,"text":2480,"url":22,"identifiers":2481},"Agrawal, 2016, Cerebral sinus thrombosis, Headache, 56, 1380, 10.1111\u002Fhead.12873",{"doi":2482},"10.1111\u002Fhead.12873",{"id":22,"text":2484,"url":22,"identifiers":2485},"Bousser, 2007, Cerebral venous thrombosis: An update, Lancet Neurol, 6, 162, 10.1016\u002FS1474-4422(07)70029-7",{"doi":2486},"10.1016\u002FS1474-4422(07)70029-7",{"id":22,"text":2488,"url":22,"identifiers":2489},"Breschet, 1829, Research of the Anatomy, Physiology, and Pathology of the Venus System with Special Emphasis on the Veins of Bones",{},{"id":22,"text":2491,"url":22,"identifiers":2492},"Bushnell, 2014, Evaluation and management of cerebral venous thrombosis, Continuum (Minneap Minn), 20, 335",{},{"id":22,"text":2494,"url":22,"identifiers":2495},"Coutinho, 2014, Declining mortality in cerebral venous thrombosis: A systematic review, Stroke, 45, 1338, 10.1161\u002FSTROKEAHA.113.004666",{"doi":2496},"10.1161\u002FSTROKEAHA.113.004666",{"id":22,"text":2498,"url":22,"identifiers":2499},"Coutinho, 2015, Cerebral venous thrombosis, J Thromb Haemost, 13, S238, 10.1111\u002Fjth.12945",{"doi":2500},"10.1111\u002Fjth.12945",{"id":22,"text":2502,"url":22,"identifiers":2503},"di Caprera, 2018, Cerebral venous thrombosis presenting like a subdural hemorrhage at magnetic resonance imaging: An Italian case report, Eur J Radiol Open, 5, 31, 10.1016\u002Fj.ejro.2017.12.001",{"doi":2504},"10.1016\u002Fj.ejro.2017.12.001",{"id":22,"text":2506,"url":22,"identifiers":2507},"Dmytriw, 2018, Cerebral venous thrombosis: State of the art diagnosis and management, Neuroradiology, 60, 669, 10.1007\u002Fs00234-018-2032-2",{"doi":2508},"10.1007\u002Fs00234-018-2032-2",{"id":22,"text":2510,"url":22,"identifiers":2511},"Ferro, 2019, Safety and efficacy of dabigatran etexilate vs dose-adjusted warfarin in patients with cerebral venous thrombosis: A randomized clinical trial, JAMA Neurol, 76, 1457, 10.1001\u002Fjamaneurol.2019.2764",{"doi":2512},"10.1001\u002Fjamaneurol.2019.2764",{"id":22,"text":2514,"url":22,"identifiers":2515},"Lee, 2020, Comparing the efficacy and safety of direct oral anticoagulants with vitamin K antagonist in cerebral venous thrombosis, J Thromb Thrombolysis, 50, 724, 10.1007\u002Fs11239-020-02106-7",{"doi":2516},"10.1007\u002Fs11239-020-02106-7",{"id":22,"text":2518,"url":22,"identifiers":2519},"Patel, 2015, Cerebral venous thrombosis: Current and newer anticoagulant treatment options, Neurologist, 20, 80, 10.1097\u002FNRL.0000000000000049",{"doi":2520},"10.1097\u002FNRL.0000000000000049",{"id":22,"text":2522,"url":22,"identifiers":2523},"Ruíz, 2004, The sphenoparietal sinus of breschet: Does it exist? An anatomic study, AJNR Am J Neuroradiol, 25, 112",{},{"id":22,"text":2525,"url":22,"identifiers":2526},"Sader, 2018, Management of venous sinus thrombosis, Neurosurg Clin N Am, 29, 585, 10.1016\u002Fj.nec.2018.06.011",{"doi":2527},"10.1016\u002Fj.nec.2018.06.011",{"id":22,"text":2529,"url":22,"identifiers":2530},"Saposnik, 2011, Diagnosis and management of cerebral venous thrombosis: A statement for healthcare professionals from the American heart association\u002F American stroke association, Stroke, 42, 1158, 10.1161\u002FSTR.0b013e31820a8364",{"doi":2531},"10.1161\u002FSTR.0b013e31820a8364",{"id":22,"text":2533,"url":22,"identifiers":2534},"Silvis, 2017, Cerebral venous thrombosis, Nat Rev Neurol, 13, 555, 10.1038\u002Fnrneurol.2017.104",{"doi":2535},"10.1038\u002Fnrneurol.2017.104",{"id":22,"text":2537,"url":22,"identifiers":2538},"Silvis, 2016, Risk factors for cerebral venous thrombosis, Semin Thromb Hemost, 42, 622, 10.1055\u002Fs-0036-1584132",{"doi":2539},"10.1055\u002Fs-0036-1584132",{"id":22,"text":2541,"url":22,"identifiers":2542},"2019, Study of Rivaroxaban for CeREbral Venous Thrombosis",{},{"id":22,"text":2544,"url":22,"identifiers":2545},"Tubbs, 2007, The sphenoparietal sinus, Neurosurgery, 60, ONS9",{},{"id":2547,"createTime":2548,"updateTime":2548,"relativeEntities":2549,"slug":2550,"properties":2551,"entityType":87,"verifyStatus":88,"verifyTime":2548,"verifyNote":89,"languages":2564,"translateLanguages":22,"viewCount":23,"primaryUrl":2565,"fullTextUrl":22,"authors":2566,"publicationType":147,"publisherRelationship":2684,"citationCount":2721,"citationInfo":2722,"publishDate":2725,"publishYear":2723,"citationAnalyzeStatus":21,"lastCitationAnalyze":22,"indexDatabases":2726,"openAccess":22,"references":2727,"isForceReanalyzing":1057},"64efcfc2-5ce3-4194-8cbc-9c9f84ce3d99","2024-10-01T10:41:59.645+00:00",[],"Granulomatous-amebic-encephalitis-following-hematopoietic-stem-cell-transplantation",{"openalex":2552,"mag":2554,"title":2556,"pm":2558,"doi":2560,"pmc":2562},{"VOID":2553},"W2409815668",{"VOID":2555},"2409815668",{"EN":2557},"Granulomatous amebic encephalitis following hematopoietic stem cell transplantation",{"VOID":2559},"26539322",{"VOID":2561},"10.4103\u002F2152-7806.166788",{"VOID":2563},"4604647",[91],"http:\u002F\u002Fsurgicalneurologyint.com\u002Fsurgicalint-articles\u002Fgranulomatous-amebic-encephalitis-following-hematopoietic-stem-cell-transplantation\u002F",[2567,2586,2603,2620,2635,2652,2669],{"id":2568,"sortIndex":23,"researcher":22,"roles":2569,"affiliations":2570,"properties":2579,"displayName":2583,"givenName":22,"familyName":22},"8efa7834-c776-4d2a-a252-78cd20dc48e4",[],[2571],{"id":2572,"sortIndex":23,"affiliation":2573,"properties":22},"39f09d68-3882-4c68-892e-9de8d62389aa",{"id":2572,"createTime":22,"updateTime":22,"relativeEntities":2574,"slug":22,"properties":2575,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":2578,"statistic":22},[],{"title":2576},{"VI":2577},"Department of Neurosurgery, Medical College of Wisconsin, Milwaukee, Wisconsin, USA",[],{"orcid":2580,"title":2582,"openalex":2584},{"VOID":2581},"https:\u002F\u002Forcid.org\u002F0000-0003-0467-3440",{"EN":2583},"Ninh Doan",{"VOID":2585},"A5101435921",{"id":2587,"sortIndex":113,"researcher":22,"roles":2588,"affiliations":2589,"properties":2598,"displayName":2600,"givenName":22,"familyName":22},"12cc5eb8-5bf9-4a24-a6eb-cf067cb22add",[],[2590],{"id":2591,"sortIndex":23,"affiliation":2592,"properties":22},"70629190-8de3-4692-922f-20caaa7a4f34",{"id":2591,"createTime":22,"updateTime":22,"relativeEntities":2593,"slug":22,"properties":2594,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":2597,"statistic":22},[],{"title":2595},{"VI":2596},"Department of Neurology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA",[],{"title":2599,"openalex":2601},{"EN":2600},"Gregory Rozansky",{"VOID":2602},"A5054017996",{"id":2604,"sortIndex":129,"researcher":22,"roles":2605,"affiliations":2606,"properties":2613,"displayName":2617,"givenName":22,"familyName":22},"19f81882-d9b9-4be3-a5b5-57ddda3de4f3",[],[2607],{"id":2572,"sortIndex":23,"affiliation":2608,"properties":22},{"id":2572,"createTime":22,"updateTime":22,"relativeEntities":2609,"slug":22,"properties":2610,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":2612,"statistic":22},[],{"title":2611},{"VI":2577},[],{"orcid":2614,"title":2616,"openalex":2618},{"VOID":2615},"https:\u002F\u002Forcid.org\u002F0000-0002-3515-278X",{"EN":2617},"Ha Son Nguyen",{"VOID":2619},"A5038959255",{"id":2621,"sortIndex":1306,"researcher":22,"roles":2622,"affiliations":2623,"properties":2630,"displayName":2632,"givenName":22,"familyName":22},"cb4c0508-d04c-4544-bb3c-06d95f6bf309",[],[2624],{"id":2572,"sortIndex":23,"affiliation":2625,"properties":22},{"id":2572,"createTime":22,"updateTime":22,"relativeEntities":2626,"slug":22,"properties":2627,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":2629,"statistic":22},[],{"title":2628},{"VI":2577},[],{"title":2631,"openalex":2633},{"EN":2632},"Michael Gelsomino",{"VOID":2634},"A5044619680",{"id":2636,"sortIndex":1326,"researcher":22,"roles":2637,"affiliations":2638,"properties":2645,"displayName":2649,"givenName":22,"familyName":22},"34dd1496-d16d-4c2c-96df-4d6a31629f3e",[],[2639],{"id":2572,"sortIndex":23,"affiliation":2640,"properties":22},{"id":2572,"createTime":22,"updateTime":22,"relativeEntities":2641,"slug":22,"properties":2642,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":2644,"statistic":22},[],{"title":2643},{"VI":2577},[],{"orcid":2646,"title":2648,"openalex":2650},{"VOID":2647},"https:\u002F\u002Forcid.org\u002F0000-0001-5317-9997",{"EN":2649},"Saman Shabani",{"VOID":2651},"A5069973098",{"id":2653,"sortIndex":1346,"researcher":22,"roles":2654,"affiliations":2655,"properties":2662,"displayName":2666,"givenName":22,"familyName":22},"9e967f9c-4361-43ac-aa83-5d26a86d5c5d",[],[2656],{"id":2572,"sortIndex":23,"affiliation":2657,"properties":22},{"id":2572,"createTime":22,"updateTime":22,"relativeEntities":2658,"slug":22,"properties":2659,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":2661,"statistic":22},[],{"title":2660},{"VI":2577},[],{"orcid":2663,"title":2665,"openalex":2667},{"VOID":2664},"https:\u002F\u002Forcid.org\u002F0000-0003-1281-5250",{"EN":2666},"Wade M. Mueller",{"VOID":2668},"A5034479560",{"id":2670,"sortIndex":1364,"researcher":22,"roles":2671,"affiliations":2672,"properties":2679,"displayName":2681,"givenName":22,"familyName":22},"13f5960d-6302-4824-a310-884db49b1e7c",[],[2673],{"id":2591,"sortIndex":23,"affiliation":2674,"properties":22},{"id":2591,"createTime":22,"updateTime":22,"relativeEntities":2675,"slug":22,"properties":2676,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":2678,"statistic":22},[],{"title":2677},{"VI":2596},[],{"title":2680,"openalex":2682},{"EN":2681},"Vijay Johnson",{"VOID":2683},"A5083065242",{"url":22,"publisher":2685,"properties":2714},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":2686,"slug":10,"properties":2687,"entityType":20,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":23,"subjectFields":2691,"manageAffiliations":2700,"indexDatabases":2706,"url":64,"thumbnailPath":22,"statistic":22,"gsStatistic":22,"type":22,"analyzePriority":22},[],{"issn":2688,"title":2689,"country":2690},{"VOID":15},{"EN":17},{"VOID":13},[2692,2696],{"id":26,"createTime":22,"updateTime":22,"relativeEntities":2693,"label":2694,"description":2695,"parentId":22,"standard":22,"scholarHubFieldId":22},[],{"EN":29},{},{"id":32,"createTime":22,"updateTime":22,"relativeEntities":2697,"label":2698,"description":2699,"parentId":22,"standard":22,"scholarHubFieldId":22},[],{"EN":35},{},[2701],{"id":39,"createTime":22,"updateTime":22,"relativeEntities":2702,"slug":22,"properties":2703,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":2705,"statistic":22},[],{"title":2704},{"EN":43},[],[2707],{"id":47,"indexDatabase":2708,"url":58,"indexYears":59,"academicFieldIds":2713,"indexDatabaseRanking":63},{"id":49,"createTime":22,"updateTime":22,"relativeEntities":2709,"label":2710,"description":2711,"key":55,"publicationTags":2712,"standard":22},[],{"EN":52,"VI":52},{"EN":52,"VI":54},[57],[61,62],{"issue":2715,"pages":2717,"volume":2719},{"VOID":2716},"19",{"VOID":2718},"459",{"VOID":2720},"6",12,{"total":2721,"publishYear":2723,"statisticByYear":2724},2015,{"2016":129,"2017":1306,"2018":129,"2019":1306,"2020":129},"2015-01-01",[63],[2728,2731,2734,2737,2740,2743,2746,2749,2752,2755,2758,2761,2764,2767,2770,2773,2776,2779,2782],{"id":22,"text":2729,"url":22,"identifiers":2730},"Abd, 2009, Scand J Infect Dis, Ante mortem diagnosis of amoebic encephalitis in a haematopoietic stem cell transplanted patient, 619",{},{"id":22,"text":2732,"url":22,"identifiers":2733},"Akpek, 2011, Transpl Infect Dis, Granulomatous amebic encephalitis: An under-recognized cause of infectious mortality after hematopoietic stem cell transplantation, 366",{},{"id":22,"text":2735,"url":22,"identifiers":2736},"Anderlini, 1994, Bone Marrow Transplant, Acanthamoeba meningoencephalitis after bone marrow transplantation, 459",{},{"id":22,"text":2738,"url":22,"identifiers":2739},"Castellano-Sanchez, 2003, Transpl Infect Dis, Acanthamoeba castellani encephalitis following partially mismatched related donor peripheral stem cell transplantation, 191",{},{"id":22,"text":2741,"url":22,"identifiers":2742},"Feingold, 1998, Bone Marrow Transplant, Acanthamoeba meningoencephalitis following autologous peripheral stem cell transplantation, 297",{},{"id":22,"text":2744,"url":22,"identifiers":2745},"Fung, 2008, Liver Transpl, Cure of Acanthamoeba cerebral abscess in a liver transplant patient, 308",{},{"id":22,"text":2747,"url":22,"identifiers":2748},"Glaser, 2006, Clin Infect Dis, Beyond viruses: Clinical profiles and etiologies associated with encephalitis, 1565",{},{"id":22,"text":2750,"url":22,"identifiers":2751},"Gupta, 2008, Pediatr Blood Cancer, Successful treatment of Acanthamoeba meningoencephalitis during induction therapy of childhood acute lymphoblastic leukemia, 1292",{},{"id":22,"text":2753,"url":22,"identifiers":2754},"Kaul, 2008, Transpl Infect Dis, Acanthamoeba infection in a patient with chronic graft-versus-host disease occurring during treatment with voriconazole, 437",{},{"id":22,"text":2756,"url":22,"identifiers":2757},"Marciano-Cabral, 2003, Clin Microbiol Rev, Acanthamoeba spp.as agents of disease in humans, 273",{},{"id":22,"text":2759,"url":22,"identifiers":2760},"Maritschnegg, 2011, J Clin Microbiol, Granulomatous amebic encephalitis in a child with acute lymphoblastic leukemia successfully treated with multimodal antimicrobial therapy and hyperbaric oxygen, 446",{},{"id":22,"text":2762,"url":22,"identifiers":2763},"Parija, 2015, Trop Parasitol, Management of granulomatous amebic encephalitis: Laboratory diagnosis and treatment, 23",{},{"id":22,"text":2765,"url":22,"identifiers":2766},"Pemán, 2008, Am J Transplant, Unexpected postmortem diagnosis of Acanthamoeba meningoencephalitis following allogeneic peripheral blood stem cell transplantation, 1562",{},{"id":22,"text":2768,"url":22,"identifiers":2769},"Satlin, 2013, Transpl Infect Dis, Fulminant and fatal encephalitis caused by Acanthamoeba in a kidney transplant recipient: Case report and literature review, 619",{},{"id":22,"text":2771,"url":22,"identifiers":2772},"Seijo, 2000, J Clin Microbiol, Granulomatous amebic encephalitis in a patient with AIDS: Isolation of Acanthamoeba sp.Group II from brain tissue and successful treatment with sulfadiazine and fluconazole, 3892",{},{"id":22,"text":2774,"url":22,"identifiers":2775},"Singh, 2006, AJNR Am J Neuroradiol, Amebic meningoencephalitis: Spectrum of imaging findings, 1217",{},{"id":22,"text":2777,"url":22,"identifiers":2778},"Stahl, 2014, Curr Opin Neurol, What is new about epidemiology of acute infectious encephalitis?, 337",{},{"id":22,"text":2780,"url":22,"identifiers":2781},"Venkatesan, 2015, Curr Neurol Neurosci Rep, Autoimmune encephalitis and its relation to infection, 3",{},{"id":22,"text":2783,"url":22,"identifiers":2784},"Visvesvara, 2013, Handb Clin Neurol, Infections with free-living amebae, 153",{},{"id":2786,"createTime":2787,"updateTime":2787,"relativeEntities":2788,"slug":2789,"properties":2790,"entityType":87,"verifyStatus":88,"verifyTime":2787,"verifyNote":89,"languages":2803,"translateLanguages":22,"viewCount":23,"primaryUrl":2804,"fullTextUrl":22,"authors":2805,"publicationType":147,"publisherRelationship":2874,"citationCount":2909,"citationInfo":2910,"publishDate":199,"publishYear":187,"citationAnalyzeStatus":21,"lastCitationAnalyze":22,"indexDatabases":2912,"openAccess":22,"references":2913,"isForceReanalyzing":1057},"e581e842-6ffc-4ce7-8560-128cd6f4dbbf","2024-10-01T09:08:24.484+00:00",[],"Resolution-of-bilateral-moyamoya-associated-collateral-vessel-aneurysms-Rationale-for-endovascular-versus-surgical-intervention",{"openalex":2791,"mag":2793,"title":2795,"pm":2797,"doi":2799,"pmc":2801},{"VOID":2792},"W1995837623",{"VOID":2794},"1995837623",{"EN":2796},"Resolution of bilateral moyamoya associated collateral vessel aneurysms: Rationale for endovascular versus surgical intervention",{"VOID":2798},"25071939",{"VOID":2800},"10.4103\u002F2152-7806.134812",{"VOID":2802},"4109168",[91],"http:\u002F\u002Fwww.surgicalneurologyint.com\u002Ftext.asp?2014\u002F5\u002F5\u002F155\u002F134812",[2806,2825,2840,2857],{"id":2807,"sortIndex":23,"researcher":22,"roles":2808,"affiliations":2809,"properties":2818,"displayName":2822,"givenName":22,"familyName":22},"3ec0c5ea-d720-4cb6-ba1b-ab8177e132e8",[],[2810],{"id":2811,"sortIndex":23,"affiliation":2812,"properties":22},"bf43a951-7315-41e6-b3e6-3debb19896d9",{"id":2811,"createTime":22,"updateTime":22,"relativeEntities":2813,"slug":22,"properties":2814,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":2817,"statistic":22},[],{"title":2815},{"EN":2816},"Department of Neurosurgery, University of Illinois at Chicago, 912 S. Wood St., M\u002FC799, Chicago, IL, USA.",[],{"orcid":2819,"title":2821,"openalex":2823},{"VOID":2820},"https:\u002F\u002Forcid.org\u002F0000-0002-1289-4596",{"EN":2822},"Sepideh Amin‐Hanjani",{"VOID":2824},"A5070619742",{"id":2826,"sortIndex":113,"researcher":22,"roles":2827,"affiliations":2828,"properties":2835,"displayName":2837,"givenName":22,"familyName":22},"f7d0b4b6-b246-4a54-98ea-e432b6108138",[],[2829],{"id":2811,"sortIndex":23,"affiliation":2830,"properties":22},{"id":2811,"createTime":22,"updateTime":22,"relativeEntities":2831,"slug":22,"properties":2832,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":2834,"statistic":22},[],{"title":2833},{"EN":2816},[],{"title":2836,"openalex":2838},{"EN":2837},"Sean Goodin",{"VOID":2839},"A5085868672",{"id":2841,"sortIndex":129,"researcher":22,"roles":2842,"affiliations":2843,"properties":2850,"displayName":2854,"givenName":22,"familyName":22},"01378a23-50d2-4bd7-bc61-1ea75efe388c",[],[2844],{"id":2811,"sortIndex":23,"affiliation":2845,"properties":22},{"id":2811,"createTime":22,"updateTime":22,"relativeEntities":2846,"slug":22,"properties":2847,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":2849,"statistic":22},[],{"title":2848},{"EN":2816},[],{"orcid":2851,"title":2853,"openalex":2855},{"VOID":2852},"https:\u002F\u002Forcid.org\u002F0000-0001-7816-2809",{"EN":2854},"Fady T. Charbel",{"VOID":2856},"A5060276061",{"id":2858,"sortIndex":1306,"researcher":22,"roles":2859,"affiliations":2860,"properties":2867,"displayName":2871,"givenName":22,"familyName":22},"1ab8ac50-b41e-4698-89e2-d625e7d52d9f",[],[2861],{"id":2811,"sortIndex":23,"affiliation":2862,"properties":22},{"id":2811,"createTime":22,"updateTime":22,"relativeEntities":2863,"slug":22,"properties":2864,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":2866,"statistic":22},[],{"title":2865},{"EN":2816},[],{"orcid":2868,"title":2870,"openalex":2872},{"VOID":2869},"https:\u002F\u002Forcid.org\u002F0000-0002-1491-4634",{"EN":2871},"Ali Alaraj",{"VOID":2873},"A5035302435",{"url":22,"publisher":2875,"properties":2904},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":2876,"slug":10,"properties":2877,"entityType":20,"verifyStatus":21,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":23,"subjectFields":2881,"manageAffiliations":2890,"indexDatabases":2896,"url":64,"thumbnailPath":22,"statistic":22,"gsStatistic":22,"type":22,"analyzePriority":22},[],{"issn":2878,"title":2879,"country":2880},{"VOID":15},{"EN":17},{"VOID":13},[2882,2886],{"id":26,"createTime":22,"updateTime":22,"relativeEntities":2883,"label":2884,"description":2885,"parentId":22,"standard":22,"scholarHubFieldId":22},[],{"EN":29},{},{"id":32,"createTime":22,"updateTime":22,"relativeEntities":2887,"label":2888,"description":2889,"parentId":22,"standard":22,"scholarHubFieldId":22},[],{"EN":35},{},[2891],{"id":39,"createTime":22,"updateTime":22,"relativeEntities":2892,"slug":22,"properties":2893,"entityType":22,"verifyStatus":22,"verifyTime":22,"verifyNote":22,"languages":22,"translateLanguages":22,"viewCount":22,"url":22,"parentIds":2895,"statistic":22},[],{"title":2894},{"EN":43},[],[2897],{"id":47,"indexDatabase":2898,"url":58,"indexYears":59,"academicFieldIds":2903,"indexDatabaseRanking":63},{"id":49,"createTime":22,"updateTime":22,"relativeEntities":2899,"label":2900,"description":2901,"key":55,"publicationTags":2902,"standard":22},[],{"EN":52,"VI":52},{"EN":52,"VI":54},[57],[61,62],{"issue":2905,"pages":2906,"volume":2908},{"VOID":184},{"VOID":2907},"155",{"VOID":184},17,{"total":2909,"publishYear":187,"statisticByYear":2911},{"2015":129,"2016":1306,"2018":129,"2019":129,"2020":1346,"2021":113,"2022":113,"2023":113},[63],[2914,2917,2920,2923,2926,2929,2932,2935,2938,2941,2944,2947,2950,2953,2956,2959,2962,2965,2968,2971,2974,2977,2980,2983,2986],{"id":22,"text":2915,"url":22,"identifiers":2916},"Amin-Hanjani, 2005, Neurosurgery, The cut flow index: An intraoperative predictor of the success of extracranial-intracranial bypass for occlusive cerebrovascular disease, S75",{},{"id":22,"text":2918,"url":22,"identifiers":2919},"Arai, 2011, Neurol Med Chir (Tokyo), Ruptured intracranial aneurysms associated with moyamoya disease: Three case reports, 774",{},{"id":22,"text":2921,"url":22,"identifiers":2922},"Baaj, 2009, Neurosurg Focus, Surgical management of moyamoya disease: A review, E7",{},{"id":22,"text":2924,"url":22,"identifiers":2925},"Borota, 1996, Neurol Med Chir (Tokyo), Intracranial aneurysms associated with moyamoya disease, 860",{},{"id":22,"text":2927,"url":22,"identifiers":2928},"Grabel, 1989, J Neurosurg, Moyamoya-like disease associated with a lenticulostriate region aneurysm.Case report, 802",{},{"id":22,"text":2930,"url":22,"identifiers":2931},"Gross, 2013, Acta Neurochir (Wien), Adult moyamoya after revascularization, 247",{},{"id":22,"text":2933,"url":22,"identifiers":2934},"Harreld, 2011, AJNR Am J Neuroradiol, Embolization of an unruptured distal lenticulostriate aneurysm associated with moyamoya disease, E42",{},{"id":22,"text":2936,"url":22,"identifiers":2937},"Houkin, 1996, Stroke, Surgical therapy for adult moyamoya disease.Can surgical revascularization prevent the recurrence of intracerebral hemorrhage?, 1342",{},{"id":22,"text":2939,"url":22,"identifiers":2940},"Kawaguchi, 1996, Acta Neurochir (Wien), Characteristics of intracranial aneurysms associated with moyamoya disease.A review of 111 cases, 1287",{},{"id":22,"text":2942,"url":22,"identifiers":2943},"Kim, 2012, Neurol Med Chir (Tokyo), Surgical treatment of moyamoya disease in adults: Combined direct and indirect vs.indirect bypass surgery, 333",{},{"id":22,"text":2945,"url":22,"identifiers":2946},"Kodama, 1978, J Neurosurg, Moyamoya disease associated with aneurysm, 565",{},{"id":22,"text":2948,"url":22,"identifiers":2949},"Korematsu, 2008, Acta Neurochir (Wien), Spontaneous resolution of isolated dissecting aneurysm on the posterior inferior cerebellar artery, 77",{},{"id":22,"text":2951,"url":22,"identifiers":2952},"Kuroda, 2001, Neurosurgery, Effects of surgical revascularization on peripheral artery aneurysms in moyamoya disease: Report of three cases, 463",{},{"id":22,"text":2954,"url":22,"identifiers":2955},"Larrazabal, 2001, Can J Neurol Sci, Endovascular treatment of a lenticulostriate artery aneurysm with N-butyl cyanoacrylate, 256",{},{"id":22,"text":2957,"url":22,"identifiers":2958},"Lee, 2012, Acta Neurochir (Wien), Long-term follow-up results in 142 adult patients with moyamoya disease according to management modality, 1179",{},{"id":22,"text":2960,"url":22,"identifiers":2961},"Ni, 2012, J Clin Neurosci, Disappearance of aneurysms associated with moyamoya disease after STA-MCA anastomosis with encephaloduro myosynangiosis, 485",{},{"id":22,"text":2963,"url":22,"identifiers":2964},"Otawara, 2007, Surg Neurol, Intracerebral hemorrhage after prophylactic revascularization in a patient with adult moyamoya disease, 335",{},{"id":22,"text":2966,"url":22,"identifiers":2967},"Pandey, 2011, Stroke, Neurosurgical advances in the treatment of moyamoya disease, 3304",{},{"id":22,"text":2969,"url":22,"identifiers":2970},"Ryan, 2012, Surg Neurol Int, Hemorrhage and risk of further hemorrhagic strokes following cerebral revascularization in Moyamoya disease: A review of the literature, 72",{},{"id":22,"text":2972,"url":22,"identifiers":2973},"Scott, 2009, N Engl J Med, Moyamoya disease and moyamoya syndrome, 1226",{},{"id":22,"text":2975,"url":22,"identifiers":2976},"Starke, 2012, Neurosurgery, Moyamoya disorder in the United States, 93",{},{"id":22,"text":2978,"url":22,"identifiers":2979},"Weinberg, 2011, Neurosurg Focus, Moyamoya disease: A review of histopathology, biochemistry, and genetics, E20",{},{"id":22,"text":2981,"url":22,"identifiers":2982},"Wong, 2009, J Clin Neurosci, Spontaneous resolution of an aneurysm arising from a penetrating branch of the middle cerebral artery, 601",{},{"id":22,"text":2984,"url":22,"identifiers":2985},"Yeon, 2011, Acta Neurochir (Wien), Incidental major artery aneurysms in patients with non-hemorrhagic moyamoya disease, 1263",{},{"id":22,"text":2987,"url":22,"identifiers":2988},"Yu, 2010, Interv Neuroradiol, Endovascular treatment of intracranial aneurysms associated with moyamoya disease or moyamoya syndrome, 240",{}]